Abstract

High-grade B-cell lymphoma with translocations involving MYC and BCL2 or BCL6, usually referred to as double hit lymphoma (DHL), is an aggressive hematological malignance with distinct genetic features and poor clinical prognosis. Current standard chemoimmunotherapy fails to confer satisfying outcomes and few targeted therapeutics are available for the treatment against DHL. Recently, the delineating of the genetic landscape in tumors has provided insight into both biology and targeted therapies. Therefore, it is essential to understand the altered signaling pathways of DHL to develop treatment strategies with better clinical benefits. Herein, we summarized the genetic alterations in the two DHL subtypes (DHL-BCL2 and DHL-BCL6). We further elucidate their implications on cellular processes, including anti-apoptosis, epigenetic regulations, B-cell receptor signaling, and immune escape. Ongoing and potential therapeutic strategies and targeted drugs steered by these alterations were reviewed accordingly. Based on these findings, we also discuss the therapeutic vulnerabilities that coincide with these genetic changes. We believe that the understanding of the DHL studies will provide insight into this disease and capacitate the finding of more effective treatment strategies.

Keywords: Double hit lymphoma, Diffuse large B-cell lymphoma, Genetic alterations, Targeted therapy, Chemotherapy

Background

Diffuse large B cell lymphomas (DLBCLs) are aggressive, heterogeneous neoplasms with distinct biological, pathological and clinical characteristics, representing ~25% of non-Hodgkin lymphomas (NHL) [1]. DLBCLs harboring translocation of MYC(8q24) and BCL2(18q21) or/and BCL6(3q27) displays a highly aggressive profile, including high incidence of advanced disease at diagnosis, and poor response to up-front R-CHOP therapy (5-year overall survival [OS] and progression-free survival [PFS] rates of 27% and 18%, versus 71% and 65% in other DLBCLs) [2]. Owing to their unique genomic features, biological behaviors, and prognosis, the subtypes were classified as a new category in the 2016 revision of the World Health Organization (WHO) classification for lymphoma. They were termed high-grade B-cell lymphoma (HGBL) with translocations involving MYC and BCL2 and/or BCL6, also called double hit lymphoma (DHL) or triple hit lymphoma (THL) [3]. DHL involves the gene translocation of MYC and BCL2 (DHL-BCL2) or MYC and BCL6 (DHL-BCL6), while THL involves the translocation of all these three genes.

Given inferior outcomes with current therapies in DHL patients, further understanding disease pathology is of great importance to developing better regimens. Herein, we reviewed current clinical management, genetic
alterations, and their physiological functions, as well as novel agents in development, hoping to enlighten future exploration in DHL. Since the majority of histological subgroups of DHLs are DLBCLs [3], this review focuses on DHLs fulfilling DLBCL histology. These DHLs were termed as DHL-BCL2 (MYC and BCL2 translocation) and DHL-BCL6 (MYC and BCL6 translocation) in this review.

**Diagnosis, prognosis, and current treatment**

**Diagnosis of DHLs**

DHLs are identified in 5–15% DLBCLs [3]. Diagnosis of DHLs requires identification of translocations of MYC (8q24) and BCL2 (18q21) or and BCL6 (3q27), which is usually accomplished by fluorescent in-situ hybridization (FISH) [4]. Up to now, no consensus has been established as to which patients should have FISH tests. Some institutions recommend FISH to all DLBCL patients (routine testing), whereas others only recommend it to certain patients (selective testing) due to high cost and low prevalence [5]. In the centers performing selective testing, decisions are made based on patients’ pathologic characteristics, including MYC and BCL2 protein expression, Ki-67 percentage and cell-of-origin (COO) subtype, etc. [6, 7].

Based on COO, DLBCL could be classified into GCB and non-GCB via immunohistochemistry test (IHC), which is the most common technique with low cost used in clinic. In academic institutions, gene expression profiling (GEP) could also be used to further classify DLBCL into GCB, ABC and unclassified subtypes. Due to different prevalence of DHL-BCL2 and DHL-BCL6 in these COO subtypes, COO diagnosis could help the decision of selective testing. However, the consistency between IHC and GEP is not 100%. Sriram Balasubramanian and colleagues reviewed 910 patients’ IHC and GEP results from PHOENIX study. IHC result was 82.7% concordant with that of GEP. Due to the cost issue, IHC is currently more accessible.

**Prognosis and risk stratification**

Even within the same molecular group, the clinical outcome can be very different. Though conflicting results were yielded from different studies when associating MYC partner to prognosis [8–11], IG translocation partner of MYC likely indicates inferior outcome, especially in DHLs [12]. Additionally, DLBCL co-expressing MYC and BCL2 (double expressor lymphomas (DEL)) are associated with significantly shorter OS and PFS in both DHL and non-DHL [2, 12–14]. Interestingly, DHL cases without concurrently expressing MYC and BCL2 had more favorable outcomes than DEL after ASCT [13]. Sha et al. defined a molecular high-grade (MHG) group in DLBCL patients based on gene expression profile [15]. The 3-year PFS of the MHG group and others treated with bortezomib plus R-CHOP were 37% and 72%, respectively. Intriguingly, only half of the MHG group was diagnosed with DHL, whereas the other half demonstrated inferior outcomes compared to the non-MHG group, irrespective of their translocation status. The majority of DHLs were classified as MHG. However, no signs of worse outcomes were observed in DHLs lacking MHG features.

When compared to DHL-BCL2/THL, DHL-BCL6, the minority of all DHL, possess distinct features in many aspects. In contrast to DHL-BCL2/THL which are distinct GCB subtypes, DHL-BCL6 can be found in lymphoma with various COO including GCB, ABC, and unclassified. DHL-BCL6 has a lower proportion of MYC+ by IHC compared to DHL-BCL2/THL, whereas DHL-BCL2/THL share similar morphology (high-grade with a starry sky appearance) and immunophenotype (CD10+, MCY+BCL2+, and MUM1) [16, 17]. Also, DHL-BCL6 tends to have a less cytogenetic complexity [18]. Recent studies indicate that compared to MYC/BCL2 lymphoma, lymphoma with BCL6 translocation has a distinct molecular profile [19–23], suggesting a distinct molecular group from the DHL-BCL2/THL, the majority of DHL. Therefore, more study should be done to investigate the molecular mechanism and category of these two subtypes.

In terms of prognosis, DHL-BCL2 and THL have similar OS [17, 24]. As for DHL-BCL6, some studies suggest that this subtype is more aggressive, frequently involving extranodal sites, and has worse OS compared to DHL-BCL2 [17, 18, 24]. However, there are contradicting results indicating that DHL-BCL6 has a similar, or even better prognosis than DHL-BCL2 [24, 25]. The conflicting conclusion may be the result of a limited sample population (~10 in most studies).

The prognosis is different within the DHL-BCL2 group. Parallely, a 104–gene double-hit signature (DHITsig) developed by Ennishi et al. distinguished a cohort of GCB-DLBCLs (DHITsig positive) from other GCB-DLBCLs (DHITsig negative) [26]. DHITsig positive group was composed of 48% non-DHL/THL-BCL2s and 52% DHL/THL-BCL2s (88% of all DHL/THL-BCL2s). DHITsig positive patients had dismal outcomes after being treated with R-CHOP in terms of DSS (BioElectric Massage) (pos vs neg, 63% vs 90%), 5-year PFS (pos vs neg, 53% vs 79%), and OS (pos vs neg, 60% vs 83%). Several literature highlighted the importance of risk stratification depending on molecular features like GEP (gene expression profile), instead of merely genetic translocation status, to avoid missing out on a cluster of high-risk patients while exposing low-risk ones to excessive therapies [27, 28].
| Treatment | Response | PFS/PFS/EFS (months) | OS (months) | References |
|-----------|----------|----------------------|-------------|-------------|
| R-CHOP ($n=35$) vs intense regimens (DA-EPOCH-R ($n=81$), R-hyperCVAD ($n=32$), R-CODOX-M/VAC ($n=11$)) | Patients with DHL who achieved first complete remission | 3-year RFS rate: R-CHOP 56% vs Intense Regimens 88% 3-year RFS rate: DA-EPOCH-R 88%, R-hyperCVAD 87%, and R-CODOX-M/VAC 91% | 3-year OS rate: R-CHOP 77% vs Intense Regimens 90% ($P=0.13$) 3-year OS rates: DA-EPOCH-R 87% vs R-hyperCVAD 90% vs R-CODOX-M/VAC 100%, $P=0.57$ | Landsburg et al. [36] |
| R-CHOP ($n=5$) vs R-CODOX-M/VAC ($n=25$) | CR rate: R-CHOP 0% vs R-CODOX-M/VAC 36% ORR: R-CODOX-M/VAC 80% | 2-year PFS rate: R-CODOX-M/VAC 47% | 2-year OS rate: R-CODOX-M/VAC 61% | Sun et al. [37] |
| R-CHOP ($n=100$) vs R-DA-EPOCH ($n=28$) vs R-Hyper CVAD ($n=34$) | CR rate: R-CHOP 40% vs R-DA-EPOCH 68% ($P=0.017$ vs. R-CHOP) vs R-Hyper CVAD 68% ($P=0.011$ vs. R-CHOP) | 2-year EFS rate: R-CHOP 25% vs R-DA-EPOCH 67% vs R-Hyper CVAD 32% 3-year EFS rate: R-CHOP 20% vs R-DA-EPOCH 67% ($P=0.004$ vs R-CHOP) vs R-Hyper CVAD 32% ($P>0.05$ vs. R-CHOP) | 2-year OS rate: R-CHOP 41% vs R-DA-EPOCH 76% vs R-Hyper CVAD 44% 3-year OS rate: R-CHOP 35% vs R-DA-EPOCH 76% ($P=0.057$ vs. R-CHOP) vs R-Hyper CVAD 40% ($P>0.05$ vs. R-CHOP) | Oki et al. [33] |
| R-CHOP ($n=100$) vs intense regimens (R-DA-EPOCH ($n=65$), R-Hyper CVAD ($n=64$), R-CODOX-M/VAC ($n=42$)) | CR rate: DA-EPOCH-R was significantly higher compared with R-CHOP, R-CODOX-M/VAC, or other/multiple* regimens | Median PFS: R-CHOP 7.8 months vs intense regimens 21.6 months | OS in intensive chemotherapy (R-DA-EPOCH, R-Hyper CVAD, R-CODOX-M/VAC) is higher than R-CHOP | Petrich et al. [32] |
| R-CHOP ($n=19$) vs R-Hyper CVAD ($n=28$) | NA | PFS: R-CHOP vs R-Hyper CVAD, $P>0.05$ | OS: R-CHOP vs R-Hyper CVAD, $P>0.05$ | Li et al. [38] |
Current chemotherapy
The standard regimen for DHL has not been established yet. When clinical trials are not available, chemotherapy is the first choice. Regimens, like R-CHOP, R-DA-EPOCH, R-HyperCVAD, and R-CODOX-M/IVAC, have been clinically evaluated in Table 1 [29].

When treated with R-CHOP, DHLs were found to be associated with inferior OS compared to other DLBCLs (median OS: 13 months vs 95 months; 3-years OS: 46% vs 75%, HR 3.04, \( P = 0.002 \)) [30]. Besides, when retrospectively evaluating application of IFRT-involved-field radiation therapy), R-CHOP and more intensive immunochemotherapy in patients with limited-stage (LS) DHL, similar PFS and OS were observed throughout the treatment groups (IFRT vs no IFRT, and R-CHOP vs more intensive immunochemotherapy) [31].

Several retrospective studies and meta-analyses have compared R-CHOP to more intensive regimens in DHL patients. Petrich et al. analyzed 311 newly diagnosed DHL patients, receiving R-CHOP (31%), R-DA-EPOCH (21%), R-HyperCVAD (21%), and R-CODOX-M/IVAC (14%). They found that intensive regimens were associated with significantly improved PFS, but not OS [32]. Oki et al. found that R-EPOCH was associated with longer EFS (HR = 0.37, \( P = 0.008 \)) compared to R-CHOP, while R-HyperCVAD did not bring more benefit [33]. A meta-analysis compared the survival outcomes in DHL patients receiving more intensive regimens (R-DA-EPOCH, \( n = 91 \), and R-Hyper CVAD or R-CODOX-M/IVAC, \( n = 123 \)) versus R-CHOP (\( n = 180 \)) [34]. First-line treatment with R-EPOCH significantly reduced progression risk compared to R-CHOP (relative risk reduction of 34%; \( P = 0.032 \)), but not OS. In all, these studies supported use of more intensive regimens like R-DA-EPOCH over R-CHOP when treating DHL patients. However, a retrospective multicenter study conducted on 90 cases of DEL patients showed no survival benefit from DA-EPOCH-R compared to R-CHOP [35]. These contradicted results indicate that prospective studies are in need.

Transplantation
Allogeneic/autologous stem cell transplant (allo-SCT/ auto-SCT) is a potentially curative option for many hematological malignancies and has been evaluated in the DHL cohort. However, most studies suggest that SCT may have a dismal effect on DHL patients.

In a multicenter study involving 311 DHL patients in North America, the response of patients receiving SCT (allo-SCT or auto-SCT) after induction chemotherapy, which includes R-CHOP, R-HyperCVAD/ MA, DA-EPOCH-R, or R-CODOX-M/IVAC, as well as other non-rituximab regimens (5%) were documented. After the first CR, the median OS is between the SCT group (\( n = 39 \)) and observation group (\( n = 112 \)) did not have a significant difference [32]. Similar results were obtained by independent studies in 2014 (\( n = 129 \)), 2017 (two studies, \( n_1 = 159 \), \( n_2 = 117 \)) and 2021 (\( n = 160 \)). Auto-SCT after a front line or intensive chemotherapy in DHL patients did not affect 3-year PFS or OS after first CR [13, 33, 36, 39]. On the other hand, these studies again emphasize the importance of intensive therapy compared to front-line therapy in improving the 3-year RFS [36]. Nevertheless, according to a 2016 trial, patients with DEL or MYC overexpression may benefit from auto-SCT following CHOP/− + R treatment, presenting a lightly longer PFS and OS [40].

Genetic alterations in DHL
DHL is accompanied by genetic and molecular features that distinguish them from other DLBCL and Burkitt. With several recent studies focusing on the genetic classification of DLBCL [19–22], we summarized genetic alterations that intensively or exclusively coincides with the translocation of MYC and BCL2 and/or BCL6, and characterized consequent functional disturbance.

Genetic alterations in DHL-BCL2
From previous publications, DLBCL subgroups C3 [20], EZB-DHIT+ [21, 22], BCL2 [19], and MYC/BCL2-DH [23] shared similar genetic profiles and unanimously encompassed dual translocations of MYC and BCL2.

Herein, we summarized genetic similarities of these subgroups and combined them into one group called DHL-BCL2 (Fig. 1). DHL-BCL2 lymphomas were exclusively germinal center lymphomas with aberrant GC formation. DHL-BCL2 lymphomas were exclusively germinal center lymphomas [16, 41], with frequent genetic alterations associated with the formation of GC [42–45]. The primary genetic lesions are alterations associating epigenetic regulators like KMT2D, EZH2, and CREBBP/EP300. DHL-BCL2 also exhibited an anti-apoptotic and pro-survival profile, with aberrant activation of BCL2 and PI3K-mTOR signaling. Inactivating lesions of the S1PR2-Gα13 axis contributes to tumor cells dissemination, while damaged TNFRSF14 leads to increased CD40 signaling. Other proto-onco mutations also occur in this subtype, including activation of MYC, JAK-STAT, and NF-kB signaling, as well as suppressing p53 pathway. Gene alteration frequency and categorizing foundation were summarized in Table 2.
Alterations relating cellular differentiation and transcription factors

In DHL-BCL2, disrupted the transcriptional process of B cell development may contribute to dysregulated GC development, altered apoptosis profile, and eventually lymphomagenesis.

Table 2 Genetic aberrations associated with DHL-BCL2 [19–23]

| Category            | Gene (frequency): cluster |
|---------------------|----------------------------|
| Transcription factors | IRF8 (22%): E+, C, B, D(T), MEF2B (21%): E+, C, B, MYC (32%): E+, C, FOXO1 (13%): E+, B, POU2F2 (9%): C, B, EBFI (27%): E+ |
| Epigenetic regulators | KMT2D (59%): E+, C, B, D(T), EZH2 (55%): E+, C, B, D, CREBBP (53%): E+, C, B, D(T), EP300 (11%): E+, B, BCL7A (28%): E+, B, ARID1A (27%): E+, T, C10orf12 (27%): E+, HIST1H1D (16%): B, SRSF2 (4%): B |
| Apoptosis           | BCL2 (70%): E+, C, B, D(T), FAS (38%): E+ |
| PI3K-mTOR           | PTEN (22%): E+, C, PIK3R1 (4%): B |
| NF-κB               | REL (40%): E+; |
| JAK-STAT            | STAT6 (19%): E+, C, B; |
| PS3                 | TP53 (44%): E+; |
| Immune              | TNFRSF14 (50%): E+, C, B, D(T), HLA-DMB (22%): E+ |
| Cell migration      | GNA13 (26.30%): E+, C, B, D(T), SIPR2 (11%): E+ |
| Others              | Chrom.12p (28%): E+, C, GNA12 (13%): E+, C, DDX3X (33%): E+, 10q23.31 (24%): C, Chrom.21 (20%): E+, HVCN1 (13%): C |

E+ - EZB-DHIT cohort, C3 cohort, B2CL2 cohort, D(T) MYC/BCL2-DH/THI cohort
Both interferon regulatory factor 8 (IRF8) and myocyte enhancer factor 2B (MEF2B) are vital transcription factors in GC formation and frequently mutated in DHL-BCL2. In normal B cells, IRF8 transactivates BCL6 and AICDA [46] and prevents B cells from p53-induced apoptosis by up-regulating MDM2 [47]. MEF2B modulates the expression of a series of genes from the cell cycle (CCND3), differentiation (BCL6) to apoptosis (TP53 and BCL2) [48]. They are preferentially expressed and frequently altered in B cell lymphomas of GC origin like DLBCL and follicular lymphoma [20–22, 49–53]. The mutation of MEF2B<sup>DR3V</sup> contributes to lymphomagenesis by enlarging GC formation, dysregulating level of BCL6 [50] and other gene targets [48], while IRFB mutation and translocation were also believed to promote lymphomagenesis [46, 51].

MYC protein plays a crucial role in cellular processes, including growth, proliferation, metabolism, and biosynthesis [54, 55]. Besides MYC translocation, mutation and amplification are also repeatedly found in DHL-BCL2 [22, 56], leading to dysregulated MYC activity and oncogenic signals. MYC translocation adjacent to IG enhancer [8] and MYC amplification engender elevated MYC expression [57, 58]. MYC mutation, on the other hand, has divergent impacts on MYC expression and clinical outcomes [56]. However, the implications of most mutations have not yet been elucidated.

Forkhead box O1 (FOXO1) fosters B cell differentiation [59], and is expressed and recurrently mutated in DLBCLs [19, 21, 22, 60, 61]. FOXO1 is restricted by PI3K signaling [62]. Its absence abrogates toxicity induced by SYK and AKT inhibitor [63]. It has been reported that FOXO1 mutation is associated with inferior prognosis [60], refractory and relapsed GCB-DLBCL [64], as well as correlations with TP53 and BCL2 mutation [64, 65]. Other transcription factors, like octamer-binding protein 2 (OCT2) which is encoded by POU Class 2 Homeobox 2 (POU2F2), has been proposed as a therapeutic target due to its role in promoting B cell proliferation in GC [66], inducing the IL-6 expression [67] and regulating SYK expression [68].

**Alterations relating apoptosis**

The BCL2 family is constituted of three subfamilies: anti-apoptotic proteins (including BCL2, BCL-XL, BCL-W, MCL-1, BFL-1/A1, and BCL-B/BCL2L10), pro-apoptotic BH3-only proteins, and pro-apoptotic effector proteins (BAX and BAK). BH3-only proteins respond to cytotoxic stimuli or extrinsic pathway signals (FAS and TNFRI), expose their BH3 domain and subsequently neutralize anti-apoptotic proteins or directly activate BAX and BAK, to initiate oligomerization, and eventually to trigger caspases-dependent apoptosis [69].

Besides BCL2 translocation juxtaposed to IGH enhancer, BCL2 mutation is also enriched in this subtype [19–23, 70]. Non-synonymous mutations of BCL2 were primarily distributed in three domains: the p53 binding site of flexible loop domain (FLD), the BH4 domain, and the region between BH3 and BH1 [70, 71], thereby promoting its anti-apoptotic effect by disrupting its interaction with p53 [72], inositol 1,4,5-trisphosphate receptor (IP(3)R) [73] and BAX [74], respectively. Moreover, recurrent mutations in the BH3 domain of BCL2 contribute to the resistance of venetoclax [75].

After stimulation by FASL, FAS(CD95) can induce apoptosis and contribute to immune contraction and cell migration [76]. In EZB-DHITsig+−, mutation and deletions are frequently observed in the intracellular death domain of FAS, resulting in apoptotic function loss and further inferior survival [77, 78]. Additionally, genetic signatures, which were associated with the depletion of immune and stromal cells and the augment of tumor cells, were enriched in the EZB-DHITsig+ cluster with FAS alteration [78].

**Alterations relating to epigenetic regulators**

Alterations of epigenetic regulating genes are the most prominent in DHL-BCL2 [19–21, 23, 79]. Some have been considered promising therapeutic targets.

Histone methylation and demethylation occur at the lysine residue of histone H3 or H4 to different degrees (mono-methylation(me1), di-methylation (me2), or tri-methylation (me3)), depending on status of active or inactive chromatin. Upon histone methylation, proteins with methyl-binding domains recognize the methylated lysine and initiate transcriptional activation or repression [80, 81].

KMT2D is a histone lysine methyltransferase that catalyzes the mono- and di-methylation of lysine 4 on histone H3(H3K4). Premature stop codons upstream of the enzymatic region can be introduced by deletion and nonsense mutation, leading to KMT2D inactivation. Missense mutations at C-terminal domains and other possible mechanisms contribute to impaired methyltransferase activity without KMT2D alteration [19–23, 43]. KMT2D lesions cause reduced H3K4 methylation and altered transcriptome, which mainly affects genes regarding cell cycle regulation, anti-apoptosis, and pro-apoptosis. Such process also contributes to increased GC formation, pro-proliferative cellular profile, inhibition of tumor-suppressive pathways, accelerated lymphoma development, and even malignant transformation when cooperate with BCL2 [43, 82].

As for H3K27, hypermethylation may cause lymphomagenesis. EZH2 is a component of polycomb repressive complex 2 (PRC2) which methylates H3K27 and
transcriptionally represses genes relating to the cell cycle checkpoint [83]. Missense mutations of EZH2 are enriched at Y641 in the SET domain and have been identified in different patient cohorts and cell lines [19–23, 83–85]. Although EZH2 with mutant Y641 showed a reduced ability to directly tri-methylate H3K27 [85], global cellular H3K27me3 level containing EZH2 Y641 is still remarkably promoted owing to the increased sub-strate preference of EZH2 for H3K27me2 and increased EZH2 stability [84, 86]. EZH2 mutation and aberrantly hypermethylated H3K27 suppress differentiation and promote proliferation of GC B cells. It also alters the expression of EZH2, MYC, and genes relating to B cell regulation decreases MHC expression, and reduces T cell infiltrate in the tumor microenvironment. When cooperating with BCL2, MYC, or BCL6/BCOR complexes, EZH2 mutation promotes lymphomagenesis [87–91]. C10orf12 was also identified to interact with histone methyltransferase PRC2. The interaction enhances activity and substrate preference of PRC2, and thereby upregulate cellular H3K27me3 levels [92].

Normally, histone acetylation dissociates its interaction with DNA, leading to genetic transcription. CREBBP and EP300 are transcriptional coactivators comprising a catalytic histone acetyl-transferase domain [93]. CREBBP and EP300 have high sequence homology, yet their function in GC development turns out to be different. Deletion of both genes results in abrogation of GC formation [94]. In DHL-BCL2, CREBBP alteration (including deletions and mutations) is more frequent than that of EP300 [19–23, 95]. Loss-of-function of CREBBP leads to loss of H3K27ac at putative enhancers, expanded GC compartment, interfered plasma cell differentiation, indirective induction of MYC level, inactive p53 acetylation, proliferative profile, and MHC II deficiency of B cells. It also induces lymphomagenesis in an HDAC3 dependent manner, especially when cooperates with dysregulated BCL2 [42, 96–98]. Mutation of EP300 hardly overlaps with that of CREBBP [99]. EP300 function repression due to mutation or BCL6 suppression reduces H3K27ac, induces cell growth, and impairs the effect of BCL6 inhibitors and anti-CD20 antibodies to DLBCL cells [99–101]. Additionally, CREBBP and EP300 mutations contribute to the polarization of tumor-associated macrophages by increasing expression of CCL2, CSF1, and IL-10 via the Notch pathway [99].

SWI/SNF chromatin remodeling complexes regulate the transcriptional accessibility of DNA by mobilizing histone octamers to adjacent DNA positions [102, 103]. Point mutations of BCL7A, a subunit of SWI/SNF complexes, is enriched in the first splice donor and results in BCL7A inactivation, damaging BCL7A binding to SWI/SNF complex [19, 21, 22, 104], while wild BCL7A exhibits a tumor-suppressing role [104]. ARIDIA is another subunit of SWI/SNF chromatin remodeling complexes. Deletions of ARIDIA may affect the regulatory effect on CDKN1A, and promote proliferation and the ubiquitin–proteasome-dependent degradation of ARID1A [105]. The mutation of ARIDIA and FOXO1 is also associated with loss of HLA-C [106]. It is worth noting that the ARID1A-deficient cancers are susceptible to the perturbation of homolog ARID1B, indicating that synthetic lethality may be a possible therapeutic option in these specific tumors [107].

Additionally, the P95 mutant of splicing factor SRSF2 identified in DHL-BCI.2 alters the binding and global splicing event of RNA, thus affecting the regulation of gene expression and leading to abnormal hematopoiesis [108, 109].

**Alterations relating to oncogenic pathways**

1. Alterations relating PI3K-Akt-mTOR and BCR-NF-κB pathway

In GCB-DLBCLs, tonic BCR signaling leads to proliferation via the activation of NF-κB [110]. c-Rel, a protein of the NF-κB family, forms homo- or heterodimer with other NF-κB subunits after upstream stimuli, and translocate to the nucleus to transcriptionally activate genes associated with survival and proliferation [111]. c-Rel is encoded by REL whose amplification has early been identified as a genetic alteration associated with GCB-DLBCL [112] and is recently recognized as an EZB-related event [21, 22]. However, although this amplification arouses increased abundance of c-Rel mRNA [113], nuclear c-Rel level and NF-κB activity do not correlate with REL amplification [113–115].

The activation of co-receptor of BCR, CD19, and SYK kinase can also trigger the signaling of the PI3K-Akt-mTOR pathway, which promotes cell survival [116]. As a negative regulator of Akt, PTEN loss caused by deletion and truncating mutation promotes tonic BCR signaling, Akt activation, and cell proliferation [20, 22, 110, 117].

2. Alterations relating JAK-STAT pathway

The JAK-STAT signaling cascade consists of three main components: a cell surface receptor, a JAK, and two STAT proteins. Once the cytokine binds to its receptor, the JAK family will be phosphorylated, resulting in the recruitment of phosphorylated and dimerized STAT proteins [118]. Subsequently, STATs are translocated to the nucleus and transcriptionally participate in cell proliferation, survival, angiogenesis, and immunity [119].
Amplification of STAT6 in DHL-BCL2 enhances JAK-STAT signaling [20, 22]. Missense mutations result in repetitive alterations in the DNA-binding domain of STAT6, especially at D419, which is both prevalent in DHL-BCL2 and R/R DLBCL [19, 64]. STAT6-D419 mutations were recognized as the gain of function mutations owing to the increased nuclear localization of STAT6, upregulated STAT6-targeted gene expression, and increased sensitivity to STAT6 inhibitors of STAT6-D419-mutated lymphomas [120–122].

(3) Alterations relating to p53

P53 is a tumor-suppressing protein encoded by TP53, which transactivates genes regarding apoptosis and cell cycle. It can be degraded by MDM2-mediated ubiquitination and proteasomal degradation and repressed by sumoylation and neddylation [123]. Mutation of TP53 occurs in ~20% of all DLBCLs [21, 124], preferentially in DHLS with MYC and BCL2 rearrangements [22, 125]. In DHL-BCL2, most mutations are located in the DNA-binding core domain of TP53, posing a deleterious effect on p53 function [125] since the transcription activity of p53 is requisite for its tumor-suppressing ability [126]. In DHLS, DHITsig positive DLBCLs [127] and the rest of DLBCLs, as well as other lymphoid malignancies mutated TP53 status [123, 124] are correlated with inferior prognosis.

(4) Other alterations relating to oncogenic pathways

Though they have not been fully elucidated, some of the mutations of GNA12 are orthologous to gain-of-function mutations of GNA13, indicating an oncogenic effect [128]. Also, activating mutations of GNA12 at the GTP-binding domain may result in aberrant MAPK/ERK signaling [129]. DDXX3X is a tumor-suppressing gene that is recurrently mutated in Burkitt lymphoma and EZH-DHIT + B cell lymphomas, and such mutation results in the truncation or loss of DDXX3X [22, 130]. In NK/T cell lymphomas, DDXX3X mutant activates NK-κB and MAPK signaling, while losing the effect in inducing apoptosis, inhibiting the activation of ERK and RelB compared to its WT counterpart [131]. HVCN1 is also frequently mutated and truncated, which might induce stronger BCR-dependent signaling, proliferation, and migration [132].

Alterations relating to immune escape

Recurrent TNFRSF14 mutations in DHLS lead to reduced expression of HVEM [19, 20, 22, 23, 78], a TNFR family protein and tumor suppressor which inhibits BCR signaling, abnormal stroma activation, and CD40 signaling through BTLA stimulation [133, 134]. Also, when triggered by LIGHT, it will render tumor B cells higher immunogenicity and sensitivity to FAS-induced apoptosis [135].

Alterations relating to cell migration

SIPR2-Gα13 (encoded by SIPR2 and GNA13, respectively) signaling regulates cell growth, confinement, and localization of B cells to GC through inhibiting Akt phosphorylation under normal physiological conditions [136], while its dysregulation promotes lymphomagenesis [136–139]. GNA13 mutation, which often co-occurs with BCL2 rearrangement [19, 20, 22, 23, 70, 79], contributes to disrupted GC architecture in lymph nodes and disseminates GC B cells to systematic circulation [137]. Furthermore, loss of function mutation of GNA13 impairs its ability in suppressing BCL2 expression [140].

Genetic alterations in DHL-BCL6

Compared to their counterparts, DHLS with BCL6 translocations are relatively minor described. As reported in multiple centers, DHL-BCL2 are mainly GCB subtypes [19, 20, 22], while GCB, ABC, and undefined lymphoma can all be identified in DHL-BCL6 [141]. Upon previous publications, genetically categorized subtypes C1 [20], BN2 [21], NOTCH-2 [19], and BCL6-DH [23] are all accompanied by the translocation of BCL6, suggesting possible similarities between DHL-BCL6 and these published subtypes.

In this review, we summarized these genetic subtypes as DHL-BCL6. Genetic alterations in DHL-BCL6 closely resemble genetic events in marginal zone lymphomas (Fig. 2) [19–22, 143]. Genetic lesions in this subtype are associated with the disruption of immune escape, Notch signaling, and ubiquitin–proteasome degradation system. Pro-proliferative signatures, including cell cycle genes mutations, BCR and NF-κB signaling activation, p53 pathways suppression, are also observed in this subtype. Detailed annotations were presented in Table 3.

Alterations relating Cellular differentiation and transcription factors

DHL-BCL6 is characterized by the dual translocation of MYC and BCL6. BCL6 is a transcriptional repressor, which is vital for the development and maintenance of GC. It regulates complex genetic networks associated with cell differentiation, DNA damage repair, apoptosis, signaling pathways, and T-B cell interactions [144]. Mutations in DHL-BCL6 that coincide with marginal zone lymphomas have been described, and the loss of KLF2 (a transcription factor involved in B cell homeostasis) increases marginal zone B cell [145].
Mutation of other transcription factors may result in the alteration of intercellular signaling. ETS1, a member of the ETS family namely FLI1, sustain proliferation and survival of B cells [146]. In ABC DLBCL, ETS1 is overexpressed, resulting in transactivation of genes relating to BCR and CD40 signaling, NF-κB/TNFα pathways, immune response, and early differentiation. Thus ETS1 overexpression which promotes
B cells growth and proliferation of [147]. ZEB2 is a transcription factor expressed in various immune cells. Loss of ZEB2 leads to impaired differentiation and IL-7 signaling, and aberrant proliferation of myeloid cells [148]. Mutation of POI12F2 is found in both DHL-BCL2 and -BCL6 cohorts [19].

**Alterations relating to oncogenic pathways**

5) Alterations relating to BCR and NF-κB signaling

Compared to DHL-BCL2, genes associated with BCR and NF-κB signaling are more prominently mutated in the DHL-BCL6 subtype, leading to up-regulated BCR signaling [19–21, 23]. BCL10 and PRKCB encode two components in the BCR and NF-κB signaling transduction [149], which are mutated and amplified in DHL-BCL6 [21, 22]. Inactivating mutations located in TNFAIP3, the negative regulator of NF-κB could cause abnormal activation of NF-κB pathway and proliferation [150]. KLHL21(CRL3, an E3 ubiquitin ligase) negatively regulating NF-κB by degradation of IKKβ [151] and affecting cell migration [152, 153], is also subjected to heterozygous loss and homozygous deletion in DHL-BCL6 [21, 22].

6) Alterations relating to the Notch pathway

Once Notch ligand binds to the Notch receptor, the latter will be cleaved by disintegrin, metalloproteinase-domain-containing protein (ADAM) at S2 site and γ-secretase at S3 site, to generate Notch extracellular domain, Notch transmembrane domain (NTMD), and Notch intracellular domain (NICD). Afterwards, NICD enters the nucleus, combines with cBF1-suppressor of hairless-LAG1 (cSL) and mastermind-like proteins (MAML1, MAML2, or MAML3), and activates the transcription of related genes [154].

The aberrantly activated Notch pathway, which promotes NF-κB signaling and cell proliferation, usually co-occurs with BCL6 translocation [19–23]. Notch targeted genes are up-regulated in this cluster, facilitating their differentiation to marginal zone cells [22, 155]. Mutated or truncated Notch2 receptors, as well as inactive mutation of Notch suppressor SPEN, were often found in this cluster, resulting in Notch2 signaling hyperactivation [156, 157]. DTX1 mutations were also identified, equally in both GCB and non-GCB DLBCLs, and are primarily enriched in the N-terminal protein-interaction domain (WWE1), where the DTX1 binds with Notch and exhibits inhibitory role [158, 159].

**Alterations relating cell cycle and p53**

Cyclin interacts with CDKs to modulate the cell cycle. Mutations located at the 260–290 amino acids of CCND3 are found both in Burkitt lymphoma and DLBCL, which is likely to increase the stability of cyclin D3, and to further promote cell cycle progression [19, 64, 130, 160]. CDKN2A encodes proteins, including p53 stabilizer ARF and p16INK4a, which halts cell cycle via antagonizing CDK4/6 to [161]. Recurrent mutations found at R80 may result in the loss of CDK4 inhibiting ability [19, 162].

Besides, p53 pathway can also be affected by the mutated TRRAP. TRRAP encodes transformation/transcription domain-associated protein (a cofactor of histone acetyltransferases), which also contributes to p53 accumulation [163]. Heterozygous loss of TRRAP, therefore, may impair p53 signaling [21, 22].

TP63 is a member of TP53 family, which encodes two isoforms of p63, including tumor suppressor Tap63 (with N-terminal transactivation domain), and a truncated form ΔNp63 (without N-terminus), possibly an oncoprotein [164]. Mutation, deletion, and TBL1XR1/TP63 gene fusion may promote oncogenesis via deregulation of p63 and BCL6, BCL2, and MYC [22, 165].

**Alterations relating to the ubiquitin–proteasome system**

The ubiquitin–proteasome system plays a key role in cellular protein degradation. In the system, polyubiquitination of the target protein is mediated sequentially by a single ubiquitin-activating enzyme 1 (E1), multiple ubiquitin-conjugating enzymes (E2), and ubiquitin-protein ligases (E3). Polyubiquitinated protein is later deubiquitinated and degraded to oligopeptides by proteasomes complex [166].

Enzymes related to this process are frequently mutated in DHL-BCL6 [19–23]. The mutation of UBE2A (ubiquitin-conjugating enzyme E2A) might affect histone H2A ubiquitination and in turn, perturb the transcriptome relating to myeloid development [142, 167]. Ubiquitin E3 ligase TRIP12 participates in bioprocesses including cell proliferation, DNA repair, and chromatin remodeling via regulating the stability of proteins including PARP1, CDKN2A, RNF168, USP7, and p53. Mutation and increased expression of ubiquitin E3 ligase TRIP12 are also detected in DHL-BCL6 [168]. As described above, mutation of E3 ubiquitin-protein ligase DTX1 affects the Notch pathway, while KLHL21 mutation results in NF-κB upregulation.

**Alterations relating to immune escape**

Surface receptors related to immune response, including CD70, B2M, HLA-B, and CD274, are recurrently mutated in DHL-BCL6 [19–21]. CD70 interacts with
CD27 on T cells, mediating T-cell-dependent cytotoxicity and immune escape [169]. CD70 expression is associated with inferior outcomes, while its mutation and deletion are extensively associated with DHL-BCL6 [21, 22, 170]. Perturbed expression of MHC class I complex on cell membrane, resulting from the mutation of its components Beta-2-microglobulin (encoded by B2M) and HLA-B, leads to decreased expression of MHC I on the cell membrane and immune escape of B cells from T cells [19, 171, 172]. CD274 or PD-L1 is the ligand of the PD-1 immune checkpoint which is expressed on T cells. Ligand binding triggers a series of downstream cascades, eventually leading to the exhaustion of T cells in the form of decreased proliferation and promoted apoptosis. Recurrent gain and amplification of PD-L1 relate to DHL-BCL6, as well as in non-GCB DLBCL [20, 173]. Besides, a higher level of PD-L1 is often associated with poor prognosis [174].

**Alterations relating to cell migration**

It has been reported that the activation of CXCR4 by its ligand CXCL12 can induce signaling relating to cell migration, survival, and proliferation. In lymphoma, the activation of the CXCL12-CXCR4 axis disseminates B cells to lymph nodes [175] and bone marrow [176] and is correlated with poor survival [177]. It also mediates the immunosuppressive environment in B cell lymphoma through recruitment of regulatory T cells [178]. Besides, the consequence of active CXCR4 signaling in lymphoma also involves oncogenesis [179] and confers resistance to PI3Kδ inhibitor [180], which is disrupted by a missense mutation in DHL-BCL6 [19]. Point mutations at the C-terminal of CXCR4, therefore, may sustain the activation of the CXCL12-CXCR4 axis and contribute to cell dissemination and disease progression [19, 21, 181].

**Other alterations**

Although mutations relating to epigenetics had been found in DHL-BCL6, its scope and frequency are much less than that in DHL-BCL2 [19–21]. Lesions affecting histone compartments, as well as epigenetic regulators including KMT2D and ARID1A, had been identified. Inactivating lesions targeting TMEM30A were identified most frequently in multiple DHL-BCL6 cohorts [19–22]. The TMEM30A-knockout model suggested a correlation between TMEM30A loss and increased tumor-associated macrophages, up-regulated B cell signaling, as well as better clinical outcomes [182].

**Targeted therapy**

The discoveries of genetic lesions of two DHL subtypes identified their distinct biological engagements. With this knowledge, the therapeutic sensitivity or resistance of different DHL subtypes might be inferred, facilitating the exploration of corresponding targeted drugs. Below we summarized novel targeted agents and categorized them based on the heterogeneous genetic alterations in different DHL subtypes. For agents not yet investigated in DHL, we discussed their anti-tumor efficacy in DLBCL and other lymphomas for reference.

**Targeted therapy for DHL-BCL2**

The therapeutic vulnerability of DHL-BCL2 lies in its most perturbed proteins, such as MYC, BCL2, and epigenetic regulators. However, due to the difficulty in MYC inhibition and lack of efficacy in BCL2 inhibitors, significant attention was drawn to the application of epigenetic regulating inhibitors in DHL-BCL2, which exhibited satisfactory effect. Inhibition in signaling pathways, such as PI3K-mTOR and JAK-STAT, was also tested in this subtype. The clinical use of these targeted agents is summarized in Table 4.

**Targeting MYC**

As described previously, MYC translocations frequently occur in both types of DHL and are often mutated in DHL-BCL2, as well as other hematological malignancies, making it an attractive target for several malignancies. However, this target has been considered undruggable for a long time since the lack of well-defined ligand binding sites and large protein–protein interaction surfaces [211]. Nevertheless, there were still plenty of efforts focusing on discovering effective molecules that directly target MYC by disrupting the MYC/Max dimerization [212, 213], such as MYCi975 [214], 10074-G5 [215], and JY-3-094 [216], or by interfering the formation of c-MYC/Max/DNA complex, like MYRA-A [217] and NSC308848 [218]. Unfortunately, none of them has been promoted to clinic evaluation mainly due to the low efficacy and/or limited in vivo tolerability. Given such a situation, novel medicinal chemistry-based pharmacophore discovery and optimization, or induced-proximity approaches with catalytical mechanisms, such as PROTAC, could be employed to improve the efficacy and broaden the therapeutic window. Instead of direct strategy, targeting MYC gene transcription or translation is an effective strategy. G-quadruplexes (also known as G4-DNA) are a tertiary structure formed by guanine-rich sequences in nucleic acids. CX-3543 (Quarfloxin) was the first G-quadruplex stabilizer entering clinical trials. It was recently found to down-regulate MYC by damaging the function of G-quadruplex binding nucleolar proteins and MYC transcription [213, 219]. Oligonucleotide and siRNA technology have also been applied to inhibit MYC gene expression [211]. OmoMYC, as a small protein
Table 4  Relevant targeted agents in hematological malignances

| Category          | Target          | Agent                      | Stage of development                                      | References                        |
|------------------|-----------------|----------------------------|-----------------------------------------------------------|-----------------------------------|
| MYC regulators   | Myc             | CX-3543 (Quarfloxin)       | Phase II (B-cell chronic lymphocytic leukemia, withdrawn)  | [183]                            |
|                  |                 | INX-3280                   | Phase II (Terminated)                                     | [184]                            |
|                  |                 | Oncormyc-NG                | Phase I (neoplasms, Terminated)                           | NCT00343148                      |
| Apoptosis protein | BCL2            | Venetoclax                 | Phase I (NHL)                                             | NCT01328626[185]                 |
|                  | BCL2 + PI3K     | Venetoclax                 | Phase I (+ bendamustine and rituximab, r/r NHL)           | NCT01994229[186]                 |
|                  | BCL2 + SYK/BTK  | Venetoclax                 | Preclinical                                               |                                   |
|                  |                 | + SYK/BTK inhibitor        | Preclinical                                               |                                   |
|                  |                 | Mcl-1                      | Phase I (r/r hematologic malignancies including NHL)      | NCT04543305, NCT05107856         |
|                  |                 | MIK665                     | Phase I (multiple myeloma, lymphoma)                      | NCT02992483                      |
|                  |                 | AMG397                     | Phase I (hematologic malignancies including lymphoma)     | NCT03465540                      |
|                  |                 | Bcl-x1                     | Phase I (lymphoma)                                       | NCT01078649                      |
|                  |                 | LCL-161                    | Phase II (multiple myeloma)                               | NCT02314052                      |
|                  |                 | SM1044                     | Preclinical (r/r lymphoma)                                | [191]                            |
|                  |                 | YM155                      | Phase II (lymphoma, B-cell lymphoma, DLBCL, terminated)   | NCT00498914                      |
| Epigenetic regulators | EZH2    | Tazemetostat                | Phase II (+ R-CHOP for DLBCL; + atezolizumab for DLBCL), Approval for FL | [193–195], NCT02889523, NCT02220842 |
|                  |                 | Valimetostat               | Phase II (adult T-cell leukemia/lymphoma)                 | [196]                            |
|                  |                 | CPI-1205                   | Phase I (DLBCL)                                           | [197]                            |
|                  |                 | PF-06821497                | Phase I (DLBCL and primary cutaneous follicle center lymphoma) | NCT03460977                     |
|                  |                 | SHR2554                    | Phase I (lymphoma)                                       | NCT03603951                      |
|                  |                 | MAK683                     | Phase II (DLBCL)                                         | NCT02900651                      |
|                  |                 | PCLX-001                   | Phase I (lymphoma, NHL)                                   | NCT04836195                      |
|                  |                 | HDAC (1,2,3,6)             | Phase II (NHL), Approval for CTCL                         | [198]                            |
|                  |                 | Vorinostat                 | Phase II (NHL), Approval for CTCL                         | [198]                            |
|                  |                 | Mocetinostat               | Phase II (lymphoma)                                      | [200]                            |
|                  |                 | CUDC-907                   | Phase I (B-cell lymphoma and DLBCL)                       | NCT02674750                      |
|                  |                 | OTX015                     | Phase II (DLBCL)                                          | [204]                            |
|                  |                 | CPI-203                    | preclinical                                              | [205]                            |
|                  | BRD2-4          | PLX-2853                   | Phase I (DLBCL and follicular lymphoma)                   | [206]                            |
|                  | BRD4            | CPI-0610                   | Phase III (myelofibrosis), Phase I (lymphoma)             | [207]                            |
|                  |                 | JQ1                        | preclinical                                              | [208]                            |
|                  | DNMT1           | Azacitidine                | + R-CHOP Phase I/II (DLBCL), Approval for myelodysplastic syndromes, AML and CML | [209], NCT01004991, NCT03450343   |
|                  |                 | Decitabine                 | + R-CHOP Phase I/II (DLBCL), Approval for myelodysplastic syndromes and myelogenous leukemia | NCT02951728                      |
containing the bHLH-zip domain of MYC, is another MYC family inhibitor [211]. OmoMYC inhibits the binding of c-MYC, n-MYC, or l-MYC to Max and prevents MYC-Max heterodimer from interacting with E-box [220, 221]. Recently, a group of natural products (Rocaglates) and their synthetic derivatives have been emerging as promising therapeutical agents for the treatment of MYC-associated lymphoma, especially those Double Hit lymphoma with concurrent MYC and BCL2 dysregulation [222, 223]. These molecules can efficiently inhibit MYC expression and tumor cell viability by stabilizing target mRNA–eIF4A interaction that directly prevents translation. In addition, PLK1 was reported as key factor on sustaining MYC activity through GSK3β-mediated MYC protein stability in DHL. Therefore, inhibition of PLK1 with small molecules, such as volasertib and Ro3280, can also downregulate the protein level of MYC [224].

Although no inhibitor of MYC is effective in DHL, given its specificity, these inhibitors are expected to be the potential therapy for DHL. In addition, MYC function can be affected by BET inhibitors via transcription and destabilization of MYC protein, which leads to the development of BET inhibitors, including JQ1, and will be further discussed in the section of epigenetic regulators [225–227].

Targeting apoptosis

The anti-apoptotic nature and up-regulated level of BCL2 in the majority of DHL-BCL2 lymphoma and other malignancies have raised interest in developing inhibitors targeting BCL2 and its family members. BCL2 inhibitors mimic BH3-only proteins which bind to the pro-survival members of the BCL2 family and thus trigger apoptosis.

Venetoclax, a BCL2 inhibitor with good efficiency in leukemia, was observed with limited activity in DLBCL patients with ORR only at 18% [185], and is now being tested as a regimen in several combination therapies including chemotherapy [228], radiotherapy [229] and targeted therapy, such as PI3K, BTK and SYK inhibitors (Fig. 3) [185, 188, 230]. In the CAVALLI phase, 2 studies of venetoclax plus R-CHOP as first-line treatment of DLBCL, the 2-year PFS and OS of venetoclax plus R-CHOP were higher than R-CHOP alone, observed in all DLBCL patients (2-year PFS: 80% vs 67%; 2-year OS: 86% vs 81%), as well as patients with BCL2+ DLBCLs and DELs. AEs were also increased in venetoclax plus the R-CHOP group but were considered manageable [187]. In a preclinical study, the combination of copanlisib (PI3K inhibitor) and venetoclax extended the median survival of the DLBCL mice model bearing BCL2 translocation and DHL-BCL2-like genetic dysregulations [188]. This synergistic effect may contribute to the inhibited PTEN and enhanced Akt pathway function during venetoclax administration [231], which partially explains the similar effect observed in the study of SYK/BTK inhibitor and venetoclax combination [189]. Besides the inhibition of the Akt pathway, inhibitors of EZH2 were also found to sensitize IGH/BCL2 translocated DLBCL cells [190]. In all, the use of BCL2 inhibitor alone may fail to achieve

Table 4 (continued)

| Category                  | Target | Agent                | Stage of development                        | References               |
|---------------------------|--------|----------------------|---------------------------------------------|--------------------------|
| JAK-STAT signaling        | STAT3  | Danvatirsen (AZD9150)| Phase II (DLBCL)                            | NCT02983578              |
|                           | JAK1 and JAK2 | Ruxolitinib | Approval for myelofibrosis and lymphoma | NCT00952289, NCT00934544, NCT01243944 |
|                           | JAK2   | Pacritinib           | Phase III (myelofibrosis) Phase I (lymphoma)| NCT04404361, NCT01430084, NCT03601819 |
| NF-κB Signaling           | IRAK4  | KT-474               | Phase I (ABC-DLBCL)                         | NCT04772885              |
| PI3K-AKT-mTOR             | PI3K   | Idelalisib           | Approval for chronic lymphocytic leukemia, Phase II (DLBCL), Phase II (+-Ibrutinib for NHL, withdrawn) Phase II (NHL, terminated) | NCT02136511, NCT03576443, NCT02662296, NCT01090414 |
|                           |        | Copanlisib           | Approval for follicular center lymphoma, Phase III (NHL) | [210] NCT02367040 |
|                           | AKT    | MK-2206              | Phase II (DLBCL)                            | NCT01481129, NCT01258998 |
|                           | mTOR   | Everolimus           | Phase III (DLBCL)                           | NCT00790036              |
|                           |        | Temsirolimus         | Approval for NHL, Phase II (DLBCL)          | NCT01180049, NCT00290472 |
a satisfactory effect in lymphoma, but the combined use of BCL2 inhibitor and other DHL-BCL2 targeted drugs is promising, especially in BCL2 aberrant DLBCLs.

Other anti-apoptosis proteins in the BCL2 family, like BCL-XL and MCL-1, have also been used in the treatment of other hematological malignancies. Among them, MCL-1 inhibitor has been tested in several clinical trials for the treatment of DLBCLs. Additionally, researches indicate that the upregulation of BCL-XL and MCL-1 may be an underlying mechanism in the BCL2 inhibitors resistance in hematological carcinoma [232, 233]. Also, dual inhibition of BCL2 and MCL-1 on DLBCL exhibits synergetic effects both in vitro and in vivo [234, 235]. Therefore, MCL-1 is considered a potential target for DLBCL, and MCL-1 inhibition may be curative for patients with Venetoclax resistance.

AMG 176, an MCL-1 inhibitor that exhibited anti-tumor activity against DLBCL and other hematological malignancies in vitro [236], has entered the Phase I study in combination with Venetoclax (NCT03797261). However, the trial is terminated due to cardiac toxicity. Other MCL-1 inhibitors, including PRT1419 (NCT04543305, NCT05107856), MIK665 (as single drug: NCT02992483, terminated, in combination with a BCL2 inhibitor, VOB560: NCT04702425) and AMG 397 (NCT03465540), had also been evaluated in Phase I studies for the treatment of hematological carcinoma including DLBCL. Most results are yet unavailable, while the trial on AMG 397 is currently on voluntary hold.

In addition to the BCL2 family, inhibitors of apoptosis (IAPs) are other sets of anti-apoptotic protein, which are mainly divided into three categories: IAP1 proteins (cIAP1, BIRC2), IAP2 proteins (cIAP2, BIRC3), and XIAP proteins (XIAP, BIRC4). These proteins are essential for activating downstream signaling of the NF-κB pathway, producing pro-survival transcriptional signals [237]. Mitochondrial protein SMAC is an endogenous inhibitor of IAPs which combines and antagonizes IAPs, subsequently activating caspase-3/7/9 and promoting apoptosis [238]. SMAC mimics are used as antagonists of IAPs, and some have entered the clinical trials as a single agent, combination therapies, and immunomodulatory agents [239, 240].

Survivin is a highly conserved member of the anti-apoptotic protein (IAPs) inhibitor family which is overexpressed in up to 60% of DLBCL cases [241]. Therefore, some Survivin inhibitors were tested on DLBCL models. Survivin inhibitor sepantronium Bromide (YM155) entered the clinical study for NHL including DLBCL, yet was terminated in phase II because of insufficient efficacy (NCT00498914) [242]. Combination therapy of YM155 with rituximab therapy was also explored. The
combined treatment of YM155 and rituximab enhances the antitumor activity of B-NHL xenografts. Compared with monotherapy, the combined treatment extends the survival time of severely combined immunocompromised mice with WSU-FSCCL and Jeko B-NHL diffuse tumors. Good antitumor activity and low toxic side effects are shown in phase II [243]. When combined with bendamustine and rituximab, stronger tumor lethality and lower toxic side effects were observed, which can decrease FLT-PET signal in lymph nodes and prolong overall survival in mice bearing disseminated DLBCL xenografts, and perhaps relapsed/refractory large B-cell lymphoma as well [244]. Another survivin inhibitor SM1044 is a new water-soluble artemisinin derivative of antimalarial drug, inducing the degradation of survivin through acetylation-dependent interaction with LC3-II to promote the apoptosis of the DLBCL cell line. It also activates the CaMKK2-AMPK-ULK1 axis, which leads to the initiation of autophagy [192].

Inhibitors of other IAP proteins are also under clinical evaluation. Xevinapant is an inhibitor of cIAP protein and is currently in clinical phase I for the treatment of lymphoma. Preclinical evaluations have shown that it has good pharmacokinetic properties in animal models [245] and the dose of less than 400 mg/day combined with daunorubicin and cytarabine can reduce drug resistance during the treatment of acute myeloid leukemia [246]. IAP inhibitor LCL-161 showed therapeutic effects in cell models of rituximab-resistant B-cell lymphoma, suggesting a potential to treat DLBCL patients previously treated with rituximab [191]. LCL161 is currently in clinical trials for a number of hematological malignancies, including B-cell lymphoma [247].

There are also apoptosis inducers, such as PCLX-001. It is an N-myristoyltransferase (NMT) inhibitor, and is currently in Phase I and is mainly used in the treatment of NHL. Treatment of PCLX-001 impacts the global myristoylation of lymphoma cell proteins and inhibits early BCR signaling, which is critical for survival [248]. In addition, PCLX-001 has a high selectivity and significantly promotes the production of numerous non-myristoylated BCR effectors, including c-MYC, NF-κB, and p-ERK. It can be used as a precision drug, with researchers predicting minimal side effects during treatment [249].

**Targeting epigenetic regulation**

(1) **Targeted histone methylation therapy**

*KMT2D* mutation leads to a significant decrease in H3K4 monomethylation in tumor cells, an increase of genomic DNA damage and mutation load, as well as transcriptional instability [250]. As mentioned above, lysine-specific histone methyltransferase *KMT2D* is one of the most frequently altered genes in DHL-BCL2 [23]. Although few drugs have been reported against *KMT2D*, novel histone demethylase inhibitors might solve the loss of methylation typically observed in *KMT2D*-inactivated tumors [251]. In addition, the *KMT2D* mutation in DHL causes DNA damage and increased transcriptional stress, resulting in the accumulation of a higher mutation load and the generation of more tumor neoantigens [252]. These changes lead to a higher level of immune cell infiltration in the tumor microenvironment, making it more sensitive to immune therapy.

Mutations in EZH2 are also prevalent in DHL patients, suggesting that EZH2 inhibitors may be a potential targeted drug for the treatment of DHL. Tazemetostat is an oral selective potent EZH2 inhibitor. It was firstly approved for clinical trials in 2013. In the phase I clinical trial, tazemetostat therapy has demonstrated preliminary efficacy in 38% of patients with relapsed/refractory B-cell lymphoma, 14% with CRR, and median progression-free survival (mPFS) of 12.4 months. Grade 3 and above adverse reactions were mainly thrombocytopenia (14%) and neutropenia (14%) [193]. The interim results of phase II clinical trial showed a significant increase in ORR in DLBCL and follicular lymphoma patients with EZH2 mutant compared with wild-type (40% vs. 18%;63% vs. 28%) [194, 195]. In addition, the Phase II clinical trial of tazemetostat combined with R-CHOP (NCT02889523) and PD-L1 antibody atezolizumab (NCT02220842) in the treatment of DLBCL are in progress.

Valemetostat, as a dual inhibitor of EZH 1/2, has shown more potent antitumor efficacy than EZH2 inhibitors [196]. In phase I a clinical trial with 15 patients with NHL patients treated by Valemetostat showed the ORR of 53% and CBR of 86%. The ORR of patients with peripheral T-cell lymphoma reached 80%, indicating the reliable efficacy of valemetostat in the treatment of NHL. CPI-1205 is a novel oral small molecule EZH2 inhibitor, which achieves demethylation by competitively inhibiting the binding of SAM to the EZH2 catalytic group. Harb et al.[197] found that, among the 28 BCL patients treated with 6 cycles of CPI-1205, one case achieved CR and five cases achieved stable disease (SD). In addition, next-generation EZH2 inhibitors, including CPI169, CPI360, MAK683, PF-06821497, and SHR2554, are currently recruiting lymphoma patients for clinical trials (NCT02900651, NCT03460977, NCT03603951).

(2) **Targeted histone acetylation therapy**

Loss-of-function mutations in genes encoding proteins with a defined role in histone acetylation (e.g., *CREBBP*...
or EP300) are commonly observed in DHL-BCL2 patients (more than 50%). Somatic mutations in CREBBP lead to impaired p53 activation and also promote the oncogenic effects of BCL6 [253]. Loss-of-function mutations in CREBBP also lead to the silencing of some genes involved in MHC-II-mediated antigen-presentation [42, 96], suggesting that it may promote the immune escape of tumor cells. Taken together, these findings indicate that the regulation of histone acetylation is a potential vulnerability of DHL targeted therapy.

Vorinostat is an oral histone deacetylase inhibitor (HDACi), which works by inducing histone acetylation to activate the expression of cell cycle factors and tumor suppressor genes. In 2014, researchers began exploring the use of Vorinostat in B-cell lymphoma (Fig. 3). In phase II clinical trial involving 39 patients with relapsed/refractory follicular lymphoma [198], the ORR was 49% and mPFS was 20 months. The major adverse reactions were thrombocytopenia and neutropenia. These results suggest that Vorinostat can provide sustained clinical benefit for B-cell lymphoma patients with controllable adverse reactions.

Panobinostat was the first HDAC inhibitor for the treatment of multiple myeloma, and in recent years it has also been explored for B-cell lymphoma. The efficacy of panobinostatin in combination with rituximab was reported in over 40 patients with relapsed/refractory DLBCL, with an ORR of 28%, CRR of 18%, and MPFS of 14.5 months [199].

Chidamide, a selective HDAC inhibitor, has been shown to have a synergistic effect with rituximab in the treatment of DLBCL in vitro and in vivo [200]. The loss of CD20 on the cell surface is the main difficulty in the treatment of relapsed/refractory DLBCL with rituximab. Chidamide significantly enhanced the expression of CD20 on the surface of DLBCL cells, thus synergizing with rituximab to exert anti-tumor effects [254]. In DLBCL xenograft mice, chidamide and rituximab synergistically induce cell death and inhibited tumor growth [200].

Batlevi et al. completed a phase II clinical trial to evaluate the effect of mocetinostat in FL and DLBCL, and the ORR and clinical benefit rate (CBR) in DLBCL patients were 18.9% and 54.1%, respectively [202]. Romidepsin, an approved macrocyclic pan-HDAC inhibitor, was shown to exert synergistic antitumor effects with GSK126, an EZH2 inhibitor, in the SU-DHL-10 xenograft model [201]. Notably, the novel dual HDAC and PI3K inhibitor CUDC-907 demonstrated excellent activity (ORR 55%) and tolerability (43% of grade ≥ 3 adverse events) in a phase I trial in patients with DLBCL, FL, and HL [203]. CUDC-907 is currently in phase II clinical trial in patients with DLBCL (NCT02674750).

(3) Targeted bromodomain and extra-terminal domain family therapy

The bromodomain and extra-terminal domain (BET) family consists of four proteins: BRD2, BRD3, BRD4, and BRDT, while its N-terminal contains two BRD modules involved in acetyllysine recognition. BRD4 is presented in several transcriptional complexes, including the cofactor regulator and p-TEFB extension factor [255]. The C-terminal domain also regulates the interactions between BRD4 and many well-known transcriptional regulators, notably p-TEFB, MYC, NF-κB, and p53 [255–257]. Although BET mutations or locations are rare, BET may be overexpressed [258]. Therefore, BET inhibition has been effective in preclinical studies of multiple cancer types, especially for many hematopoietic system cancers that rely on constant BRD4 activity to express MYC [259–261].

OTX015 is the first BET inhibitor (BETi) to reach clinical trials. Amorim et al. [204] conducted a phase I clinical trial in 17 DLBCL patients treated with OTX015, which showed a CBR of 47%, suggesting that OTX015 may have potential antitumor activity against lymphoma. The most common grade 3/4 ADRs included thrombocytopenia (58%), anemia (27%), and neutropenia (22%). Further studies showed that OTX015 can inhibit TLR/NF-κB and JAK/STAT signaling pathways by down-regulating MYC expression and play a targeted therapeutic role [259]. In DHL/THL model, OTX015 (Birabresib) combined with BCL2 antagonist (such as Venetoclax) synergistically inhibited the malignant proliferation of DHL/THL cells [262], supporting the combining use of BETi and BCL2 inhibitors against MYC-driven lymphoma. A recent study showed that nonbenzodiazepine BETi, PLX-2853, synergizes with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL2 expression [206]. Similarly, in DHL patients, resistance to venetoclax was overcome by the use of the BET inhibitor CPI-203, possibly due to the down-regulation of BCL2-like protein (BFL1) [205]. In phase I clinical trial with 44 patients with relapsed/refractory lymphoma (DLBCL, FL, and HL) enrolled, 12 patients achieved a moderate response, and 2 patients with DLBCL achieved CR after 5 and 6 cycles of CPI-0610 (a highly selective BETi) treatment, respectively [207]. The treatment of IQ1 (a classic inhibitor of BRD4) extended survival in a mouse xenograft model of MYC-driven lymphoma [208], suggesting that BETi has broad therapeutic potential in DHL that is highly associated with MYC.

(4) Targeted DNA methylation therapy
DNA methylation is one of the most widely studied epigenetic modifications [251]. DNA methylation refers to the formation of 5-methylcytosine by adding methyl at the 5' end of cytosine nucleotide of C-phosphodiester-G (CpG) under the catalysis of DNA methyltransferase (DNMT). A conformational change in the methylated CpG sequence prevents transcription factors from binding, thus silencing the expression of methylated genes [263]. In normal cells, CpG islands are usually in a non-methylated or hypomethylated state, and hypermethylation will inhibit the expression of genes. Some studies suggested that high expression of DNMT3b may be associated with a poor prognosis of DLBCL. The FDA-approved DNMT inhibitors, 5-azacitidine, and decitabine, effectively demethylate DNA and induce the expression of related tumor suppressor genes [251]. In phase I clinical trial [209] involving 33 patients with DLBCL and high-grade follicular lymphoma, 5-azacitidine combined with R-CHOP regimen showed a higher objective response rate (ORR), complete response rate (CRR), and lower incidence of ADRs than R-CHOP.

**Targeting oncogenic pathways**

(1) Targeting JAK-STAT Signaling

The JAK/STAT pathway is often abnormally activated in patients with lymphoma, especially in DHL-BCL2, making it a promising target [119]. Disrupted or dysregulated JAK-STAT functionality could result in an altered microenvironment to allow for immune evasion of tumor cells [264]. STAT3 expression and activation are significantly higher in ABC DLBCL cell lines and these cell lines demonstrate higher NF-κB activity than those with low STAT3 activity [265]. Knockdown of STAT3 in mouse xenografts models suppressed the growth of ABC DLBCL tumors, validating STAT3 as a therapeutic target in this subtype of DLBCL. Due to the difficulties in developing inhibitory molecules for STAT3, plenty of effort was put into the downregulation of STAT3.

SD-36, a novel selective STAT3 degrader, can significantly and selectively degrade STAT3 in different cell lines [266]. According to preclinical data, SD-36 had a significant inhibitory effect on the growth of five DLBCL cell lines. What's more, SD-36 effectively inhibited tumor growth at 100 mg/kg in the SU-DHL-1 xenograft model and had a complete and long-lasting PD effect in inducing STAT3 degradation in vivo [267].

Danvatirsen (AZD9150) is an antisense oligonucleotide designed to reduce the production of STAT3. Depletion of STAT3 with AXD9150 in KARPAS-299 and SUP-M2 cells and xenograft models rapidly induced apoptosis and reduced the expression of STAT3 pro-survival targets, including MCL-1, c-MYC, BCL6, CYCLIN D1, BIRC5 (SURVIVIN), and IL2Rα [268]. These findings led to a phase I dose-escalation study of AZD9150 in patients with advanced cancer, including 12 lymphoma patients, 7 of them with DLBCL. Anti-tumor activity was shown in these heavily pretreated patients [269, 270]. It is currently used as the treatment of solid tumors and lymphomas (including DLBCL) that have relapsed or are ineffective against multiple chemotherapy regimens.

The targeting inhibition of STAT3 also can be achieved by inhibition of its upstream kinase including JAK1 and JAK2. Ruxolitinib, a non-selective JAK1 and 2 inhibitor that blocks phosphorylation of STAT1 and STAT3, has been approved for primary myelofibrosis [271]. Phase I/II studies evaluating this agent either as monotherapy or in combination with bortezomib in relapsed/refractory DLBCL are ongoing [272]. Pacritinib (formerly SB1518) is an oral small molecule that selectively and potently inhibits JAK2, showing promising in vitro activity in JAK2-dependent DLBCL cell lines independent of JAK2 mutational status [273]. In a phase I study in 34 patients with relapsed or refractory lymphomas, including DLBCL, pacritinib demonstrated a favorable toxicity profile [274].

(2) Targeting PI3K-AKT-mTOR signaling pathway

As previously mentioned, the PI3K/AKT/mTOR pathway was proved to play an essential role in the development and progression of many hematological malignancies, including DLBCL [275]. Inhibitors of this pathway are mainly composed of PI3K, Akt, and mTOR inhibitors.

There are many PI3K inhibitors currently in the market or clinical trials stage for the treatment of hematological tumors. Idelalisib has demonstrated antitumor activity in indolent B-NHL (iB-NHL) [276] but it is less effective in the treatment of DLBCL as a single agent regimen (Fig. 3). When combined with anti-CD20 monoclonal antibodies or BTK inhibitors, anti-tumor efficacy could be. Through complementary mechanisms, combined use with BTK inhibitors can enhance the sensitivity of DLBCL cells, overcome drug resistance, and enhance tumor lethality [277]. So far, some combination regimens have reached clinical trials [278].

Copanlisib was approved for the treatment of follicular center lymphoma [210]. Preclinical experiments have shown that Copanlisib exhibits cell-type-specific cytotoxicity at nanomolar concentrations against DLBCL cell lines. A phase II clinical trial showed that the ORR of all types of DLBCL is 25%, and the ORR for ABC-DLBCL is 38%[279].
Enzastaurin is currently in phase III. It can delay the deterioration of DLBCL despite its poor treatment effect, and have low toxicity and side effects [280]. The first result about enzastaurin for relapsed/refractory DLBCL patients in Phase II was published in 2007 [281]. It showed that none of the disease-related parameters were correlated with response to enzastaurin. Despite the low response rate, the long-term response and the good safety in Phase II warrant further evaluation of enzastaurin together with R-CHOP therapy. Besides, a synergistic effect of enzastaurin with bortezomib and gemcitabine was found in a xenograft model of GCB-DLBCL [282].

The AKT inhibitor MK-2206 is in phase II and is mainly used for the treatment of non-small cell lung cancer, colorectal cancer, while also exhibiting a therapeutic effect on DLBCL. The combination of MK-2206 and mTOR inhibitor nelfinavir can overcome the drug resistance of mTOR inhibitors in DLBCL, reduce the viability of DLBCL cells and halt the cell cycle, promoting cell apoptosis [283]. MK-2206 monotherapy kills lymphoma cells by reducing the level of p-AKT, inhibiting the downstream targets of AKT signaling, and inducing Rictor and phosphatidylinositol 3-kinase expression. The sensitivity of MK-2206 is related to the activation state of AKT in DLBCL cells. Although monomer therapy is also effective, AKT inhibitors are combined with other targeted drugs for better clinical efficacy [284].

Everolimus is an mTOR inhibitor that was approved in 2003 to treat breast cancer and kidney disease. Its research for DLBCL is in phase III studies which showed that oral Everolimus can induce BLDCL cell cycle arrest. According to the result of the Phase I study, the best dose of Everolimus is 10 mg/d [285]. Results from the phase II study showed the ORR of Everolimus DLBCL is 30%. Meanwhile, Everolimus combined with rituximab hassled to stronger cell lethality. The objective response rate was 38%, the complete response rate was 13%, and there was no increase in toxicity [286].

Temsirolimus is also an mTOR inhibitor approved for the treatment of NHL in 2007 [287]. It is in phase II for DLBCL. It can inhibit the growth of GCB-DLBCL and ABC-BLDCL cells (GCB = 30–66%, ABC = 45–57%). Combination therapy enhances its therapeutic effect, and combined with different drugs can be used to treat different types of DLBCL. For example, its combination with idelalisib enhanced the lethality of GCB-DLBCL and ABC-BLDCL cells, while combining with ibrutinib or bortezomib, a better therapeutic effect on ABC-DLBCL or GCB-DLBCL was observed, respectively [288].

**Other therapies**

Since DHL-BCL2 is accompanied by a high frequency of TNFRSF14 and ARID1A mutation, certain unique vulnerabilities were found in these subsets of tumors. As mentioned above, TNFRSF14 mutation brings about reduced HVEM levels, resulting in BTLA-mediated proliferation and CD40 signaling. Stimulation of HVEM by human LIGHT, its ligand, renders NHL more immunogenetic and sensitive to Fas-induced apoptosis, without inducing proliferation [135]. Also, restoration of HEVEM ectodomain by soluble HVEM protein or HVEM-producing and CD19-targeted CAR-T cells were tumor-suppressive in MYC+/BCL2+ DLBCL cell lines and BCL2 overexpressing lymphoma xenograft model, respectively [134]. These results indicated the breakthrough point for the intervention of immunotherapy in DHL-BCL2.

**ARID1A** and its homolog **ARID1B** have a synthetic lethal relationship. In ARID1A mutated cancers, the comutation of ARID1B destabilizes the SWI/SNF complex and damages cell proliferation, suggesting a potential target for malignancies harboring ARID1A mutations [107]. Also, researchers found that tumors with ARID1A deficiency were sensitive to immune checkpoint blockade (targeting PD-1–PD-L1), bringing a novel perspective for treating DHL-BCL2 [289].

**Targeted therapy for DHL-MYC/BCL6**

Compared to DHL-BCL2, targeted agents for DHL-BCL6 were less subtype-specific due to insufficient understanding of its biology and diverse cell-of-origin. Here, we selected drugs targeting genetically disturbed proteins or pathways found in DHL-BCL6, hopefully providing insight into the treatment of DHL-BCL6. Clinical tests of these inhibitors are summarized in Table 5.

**Targeting oncogenic pathways**

1. **Targeting Notch pathway**

Despite the frequent activation of the Notch pathway in DHL-BCL6, drugs targeting this cascade were rarely tested in DHLs, even DLBCLs. Inhibition of the γ-secretase is a common strategy in targeting the Notch pathway, which is mainly used in solid tumors [308], with a few were tested in hematologic malignancies in pre-clinical studies. Z-IL-CHO (GSI-XII) can reduce the mRNA content of HES1 in TMD8 cell lines established from DLBCL patients, proving its potential therapeutic effect in DLBCL [291]. A combination of Z-IL-CHO and bortezomib can enhance the cytotoxicity of bortezomib in multiple myeloma. This process is mainly caused by the synergistic inhibition of chymotrypsin-like proteasome...
| Category                   | Target                  | Agent             | Stage of development                                      | References               |
|----------------------------|-------------------------|-------------------|-----------------------------------------------------------|--------------------------|
| Notch γ-secretase          | MK-0752                 | Phase I (CLL, terminated) | NCT00100152                                              |
|                            | Z-LLNle-CHO             | Preclinical (precursor B-cell acute leukemia) | [290]                                                   |
|                            | Z-IL-CHO                | Preclinical (DLBCL)  | NCT04855136                                              |
| Unidentified               | Crenigacestat           | Phase I /II (multiple myeloma and precursor T-cell lymphoblastic leukemia) | NCT02518113              |
| Unidentified               | CB-103                  | Phase I (NHL)      | NCT03422679                                              |
| BCR signaling              | BTK                     | Ibrutinib          | Approval for mantle cell lymphoma, Chronic lymphocytic leukemia/small lymphocytic lymphoma, DLBCL | NCT01236391              |
|                            | SYK                     | Fostamatinib Disodium (R788) | Approval for DLBCL                                      | NCT02076399              |
| Ubiquitin proteasome system| IRAK4                   | KT-474             | Phase I (ABC-DLBCL)                                       | NCT04772885              |
|                            | CRBN                    | Lenalidomide       | Phase II (+ DA-EPOCH-R, lymphoma including DLBCL)        | NCT02213913 [292]        |
|                            |                         |                   | Phase II (+ R-CHOP, lymphoma including DLBCL)             | NCT00670358 [293]        |
|                            |                         |                   | Phase II (+ R-CHOP21, lymphoma including DLBCL)           | NCT00907348 [294]        |
|                            |                         |                   | Phase II (+ rituximab, lymphoma including DLBCL)          | NCT00294632 [295]        |
|                            |                         |                   | Phase II (+ ibrutinib and rituximab, r/r DLBCL)           | NCT02077166 [296]        |
|                            |                         |                   | Phase III (maintenance regimen, DLBCL)                   | NCT01122472 [297]        |
|                            |                         |                   | Phase III (NHL and DLBCL)                                | NCT00312845              |
|                            |                         |                   | Phase III (maintenance regimen, DLBCL)                   | NCT01324596              |
|                            |                         |                   | Phase III (maintenance regimen, DLBCL)                   | NCT02481310              |
|                            | Bortezomib              | Approval for multiple myeloma, | NCT02268890                                              |
|                            |                         |                   | Phase II (NHL and DLBCL)                                 | NCT0312845               |
|                            |                         |                   | Phase II (NHL and DLBCL)                                 | NCT01324596              |
|                            |                         |                   | Phase II (NHL and DLBCL)                                 | NCT02481310              |
|                            | ixazomib                | Approval for multiple myeloma, | NCT03173092                                              |
|                            |                         |                   | Phase III (NHL and DLBCL)                                | NCT00312845              |
|                            |                         |                   | Phase III (NHL and DLBCL)                                | NCT01324596              |
|                            |                         |                   | Phase III (NHL and DLBCL)                                | NCT02481310              |
|                            | b-AP15                  | Preclinical (DLBCL) | NCT02268890                                              |
|                            |                         |                   | NCT03173092                                              |
|                            |                         |                   | NCT02481310                                              |
|                            |                         |                   | NCT03588078                                              |
|                            | p53                     | Eneretapopt (APR-246) | Phase II (Leukemia)                                      | NCT02545283              |
|                            | MDM2                    | Idaasinutin (RG7388) | Phase III (+ Cytarabine, leukemia)                        | NCT03478514              |
|                            | XPO1                    | Selinexor (KPT-330) | Approval for r/r DLBCL and r/r multiple myeloma           | NCT03547115; [300]       |
| Proliferation              | CDK4/6                  | Palbociclib        | Phase II (+ ibrutinib for mantle cell lymphoma and B-cell lymphoma) | NCT01739309              |
|                            | CDK9                    | Abemaciclib        | Phase II (MCL)                                           | NCT02684617 (Terminated); [234] |
|                            | Dinaciclib              | Phase Ib (+ Pembrolizumab for DLBCL)                     | NCT02684617 (Terminated); [234] |
|                            |                         | Voruciclib         | Phase I (DLBCL)                                          | NCT03547115; [300]       |
|                            | CXCR4                   | PF-06747143        | Preclinical                                               | [301]                    |
|                            | CXCR4-directed          | T22-AUR            | Preclinical                                               | [302]                    |
|                            | auristatin E nanoconjugate |               |                                                           |                          |
|                            | CXCR4-modified          | CD19 CART cells    | Phase I (refractory NHL)                                 | NCT04684472              |
|                            | radioligand therapy     |                   |                                                           |                          |
by Z-IL-CHO and bortezomib, rather than the inhibition of the Notch pathway, which provides a choice for the combined treatment of multiple myeloma [309]. Z-LLNle-CHO (GSI-I), crenigacestat, and MK-0752 all exhibited inhibitory activity against γ-secretase and were also tested in different hematology malignancies, yet no studies in DLBCL were launched [290, 310–312].

Another molecule, CB-103, acts as a disruptor of NICD protein–protein interaction and inhibitor of the active forms of Notch receptors. It targets various cancers with Notch overexpression resistant to Notch inhibition by GSIs and monoclonal antibodies while eliminating the gastrointestinal toxicity and expanding the therapeutic window of the first—and second-generation Notch inhibitors [313, 314]. Likely, evaluation of these inhibitors may yield unexpected results in the DHL-BCL6 subtype.

(2) Targeting BCR Signaling

The BCR complex and associated protein tyrosine kinases are essential for normal B-cell function and antibody production. BCR cross-linking activates 3 main pathways: BTK, PLC-γ2, and PI3K [315]. Constitutively activated BCR signaling is linked to the initiation and maintenance of B-cell malignancies, especially in the ABC-DLBCL. Drugs targeting these proteins either as adjuncts to R-CHOP in the frontline setting or as monotherapy/combination therapy in the relapsed/refractory setting are under evaluation [316].

Ibrutinib, a first-in-class small molecule that selectively covalently binds to the cysteine residue (Cys-481) of the active site of BTK, irreversibly inhibits its activity (Fig. 4) [317]. For patients with ABC DLBCL, the effective rate of single ibrutinib in relapsed/refractory patients can be as high as 37%, but for patients with GCB DLBCL, the effective rate is only 15%. In terms of combination therapy, the combination of ibrutinib and R-CHOP can significantly improve the efficacy of R/R DLBCL, and the effectiveness of the GCB subtype is still inferior to that of the ABC subtype [318].

Fostamatinib Disodium (R788) is a prodrug of the active metabolite R406, which is an oral SYK inhibitor with IC50 of 41 nM. It strongly inhibits SYK but does not inhibit Lyn, while the effect on Flt3 is 5 times weaker [319]. However, the results of two pivotal phases III clinical trials OSKIRA-2 and OSKIRA-3 showed that compared with the placebo group, fostamatinib did not show significant clinical benefit in ABC DLBCL [320]. At the same time, phase II clinical studies of hematological malignancies did not show positive results.

Cerdulatinib (PRT-062070) is an orally active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and SYK, respectively [321]. It has broad anti-tumor activity in both ABC and GC cell lines of diffuse large B cells at least in part by inhibiting SYK and JAK pathways [322].

Enzastaurin, an oral PKC-β agent, showed limited cytotoxicity in clinical phase I trials and achieved encouraging clinical effects in the phase II trial of DLBCL as induction therapy [323]. However, the PRELUDE randomized phase III trial of R-CHOP ± enzastaurin did not improve PFS as a primary endpoint.
(3) Targeting NF-κB Signaling

The excessive activation of NF-κB dependent gene expression is an important characteristic of the more aggressive ABC DLBCL subtype [324]. The formation of the CARD11/ BCL10/MALT1 complex activates IKK, causing phosphorylation and breakdown of IκB, and ultimately leading to the activation of NF-κB [325]. In addition, the adaptor protein MYD88 acts as a mediator, which can accept Toll-like receptor signals to activate NF-κB, and MYD88 is highly mutated in ABC DLBCL [326]. The NF-κB pathway as a therapeutic target was first demonstrated by the IκB kinase (IKK) complex inhibitors in selective inhibition of ABC DLBCL cell lines. Moreover, proteasome inhibition has been shown particular efficacy in patients with ABC DLBCL.

KT-474, a novel heterobifunctional IRAK4 degrader that targets both IRAK4 and IMiD biology leads to potent cell kill in ABC DLBCL lines harboring MYD88 L265P through down modulating survival signals, including NF-κB and autocrine IL-6/IL-10 engagement of the JAK-STAT3 pathway. KT-474 induced superior cellular toxicity compared to IRAK4 kinase inhibition as determined by lower IC50 and induction of apoptosis. MYD88-mutated ABC-DLBCL cell lines are more sensitive to KT-474 exposure as compared to wild-type. A combination of KT-474 in conjunction with ibrutinib, venetoclax and umbralisib shows a synergistic effect in the OCI-LY10 cell line.

Targeting ubiquitin–proteasome system

As many pathways are interfered with by genetic alteration, remodelling intercellular signaling via the inhibition of ubiquitin–proteasome-dependent degradation has been considered as a possible strategy, since several important proteins, including IκB, the inhibitory switch of NF-κB, p53, a tumor suppressor, and other ubiquitin-conjugating enzymes found to be mutated in the DHL-BCL6 case when treated with lenalidomide follow-up studies [327], which is more prominent in the DHL-BCL6.

Lenalidomide targets the E3 ubiquitin ligase component cereblon that modulates the interferon regulatory factor 4 and down-regulates the NF-κB pathway in ABC-DLBCL (Fig. 4) [328]. In clinical studies, lenalidomide exhibited promising efficacy in DLBCLs, especially in non-GCB subtype, with significantly prolonged PFS and OS, either as a single agent [293] or in combination with chemotherapies (R-CHOP and similar therapies) [293, 294] or other regiments(rituximab or ibrutinib) [295, 296], as well as being maintenance strategy [297]. For DHL, the response to lenalidomide plus DA-EPOCH-R is less satisfied compared to DELs in terms of disease remission, PFS, and CNS involvement [292]. The difference may be attributed to the small DHL patient group or the higher correlation between DEL and non-GCB lymphoma, which respond better to lenalidomide-based therapies [292, 299]. Durable remission was observed in a DHL-BCL6 case when treated with lenalidomide following salvage chemotherapy [330]. Hence, more and larger clinical trials may be beneficial.

Bortezomib (PS-341) is the first generation of protease inhibitor with Ki of 0.6 nM, which shows good selectivity for tumor cells (Fig. 4) [331]. Bortezomib can prevent the degradation of IκB, keeping NF-κB in its inactive form [332]. In the R/R DLBCL population, bortezomib alone did not bring great efficacy, but when combined with chemotherapy (DAEPOCH-R), the combination achieved better efficacy (response rate to 83% vs 13%; P<0.001) and overall survival (10.8 vs 3.4 months; P=0.003) in ABC vs GC DLBCL [333]. More recently, results of the randomized phase II PYRAMID study revealed no benefit to the use of bortezomib as an adjunct to R-CHOP in the frontline setting for non-GC DLBCL patients [334]. In a word, its clinical application is limited due to short drug effect time and severe dose-dependent neurological side effects [335].

Compared with the first generation of proteasome inhibitors, the second generation has oral biological activity, improved pharmacokinetics, and reduced neuropathy. Ixazomib is the first proteasome inhibitor that can be administered orally [336]. At present, preclinical experiments have proved that ixazomib has not only anti-tumor activity in DLBCL cell lines, but also inhibitory activity in DLBCL cell lines that have translocation of MYC and BCL2, and its IC50 value is 40-200 nm. A DHL xenograft mouse model showed anti-tumor activity at a clinically achievable drug concentration. At a dose of 7 mg/kg, the maximum tumor inhibition rate (TGI max) is 64%. Therefore, ixazomib is a potential drug for the treatment of DHL-BCL2, and its combination with CHK2 inhibitors provides a potential treatment option for drug-resistant DLBCL and DHL-BCL2 [337].

B-API15 is a specific inhibitor of the deubiquitinating enzymes, and subsequently, inhibits the migration of DLBCL tumor cells and induces apoptosis. Preclinical experiments have shown that B-API15 promotes apoptosis by inhibiting the activity of proteasome DUB (USP14 and UCHL5) in GCB and ABC-DLBCL cell lines [338], and inhibits WNT/β-catenin and TGFβ/Smad pathways to prevent DLBCL tumor cell migration. B-API15 directly inhibits c-MYC protein, rather than inhibiting BCL2, but it can cause a decrease in BCL2 mRNA levels.
Therefore, b-AP15 is not only a potential treatment for DLBCL but also DHL-BCL2 [298].

**Targeting p53 signaling**

Although 50% of tumors carry TP53 mutations, the development of p53-targeted therapies is challenging [339]. Some TP53 mutants do not encode a complete protein, and p53 itself, as a transcriptional factor, does not have an "active pocket" for small molecules to bind [340]. Current strategies targeting p53 mainly include targeting mutant p53 [341], synthetic lethality, and targeting MDM2-dependent p53 degradation [342]. However, these agents are only tested in leukemia, while studies in lymphoma remain unperformed [343–345].

XPO1 is a nuclear export receptor, which is involved in the nuclear-cytoplasmic transport of proteins bearing nuclear export signal (NES), and multiple RNA species [346]. XPO1 is usually overexpressed and/or mutated in the DLBCL cell lines, which causes poor nuclear retention of several proteins including several tumor suppressors like p53, BRCA1/2, and p27 [346, 347]. In addition, clinical research shows that high XPO1 expression has a significant adverse prognostic impact in DHL patients, especially in those with BCL2 overexpression [348]. Inhibition of XPO1 can down-regulate the expression of MYC in a variety of DHL cell lines [349].

Selinexor (KPT-330) is a first-in-class oral, biologically effective, and selective XPO1 inhibitor, which has been approved by the FDA for the treatment of heavily pre-treated R/R DLBCL and R/R multiple myeloma (Fig. 4) [299]. Selinexor can effectively down-regulate MYC protein expression and thus reprogram the gene expression of MYC downstream. Combined use of XPO1 and BCL2 inhibitors can synergistically induce the apoptosis of DHL tumor cells in vitro, and most importantly, block tumor progression and spread in vivo [349]. The effect of Selinexor has been confirmed in high-risk molecular DLBCL (both GC and non-GC subtypes), de novo, and transformed DLBCL and double-hit lymphomas [350].

**Targeting cell cycle**

CDKN2A is a tumor suppressor gene located on chromosome 9, encoding p16CDKN2A protein, which can inhibit the activity of CDK and regulate the G1 cell cycle [351]. Inactivation of CDKN2A may result in uncontrolled cell growth and proliferation. CDKN2A is frequently deleted, mutated, or hypermethylated in many tumors, including T-cell lymphoma, and is believed to be the second most commonly inactivated gene in cancer after p53 [351]. It is generally thought that CDKN2A gene loss-of-function mutations may lead to abnormal activation of CDK2/4/6, so CDK inhibitors may be a potential treatment for patients with CDKN2A mutations [352].

In addition, the same highly frequent alteration of the CCND3 gene was observed in MYC-BCL6 DHL patients, and the high expression of CCND3 can lead to downstream CDK4/6 activation, resulting in abnormal cell proliferation [353]. Therefore, CDK inhibitors may serve as potential therapeutic agents against MYC-BCL6 DHL.

Both palbociclib and abemaciclib are orally selective small-molecule CDK4/6 inhibitors that inhibit the progression of the cell cycle from G1 to S phase and block DNA synthesis [354]. A recent study found that both palbociclib and abemaciclib play a role in high-grade B-cell lymphoma with abnormal expression of CCND3 [355]. Pan-CDK inhibitor dinaciclib is proved to play synergistic induction of apoptosis in high-risk DLBCL when in combination with BCL2 inhibitor venetoclax [234]. In addition, CDK inhibitors such as flavopiridol and seliciclib were also found to be effective in BCL [356, 357], suggesting that targeted inhibition of CDK activity may indeed be a feasible treatment for DHL-BCL6. It is worth mentioning that a series of PROTACs studies targeting CDK has been progressively reported recently [358, 359], which may provide more treatment options for DHL.

**Targeting CXCR4**

As mentioned in the section of “3.1.6 Alterations relating cell migration”, the activation of the CXCR4 axis leads to cell dissemination to extranodal location. Two major strategies to target CXCR4 are direct inhibition and combination agents, aiming to induce cell death in CXCR4+ tumor cells.

Direct CXCR4 antagonists, including AMD3100(Plerixafor), AMD070, and WIK, demonstrated a pro-apoptotic effect in CXCR4+ DLBCL cells via modulation of JNK, ERK, NF-κB/ BCR, and BCL2 targets [176]. PF-06747143, a CXCR4 inhibiting IgG1 antibody, inhibits the signaling pathway and cell migration of lymphoma cells, reducing the bone marrow infiltration of Burkitt’s lymphoma in vivo [301]. In light of this, the safety and effect of CXCR4 targeted agents have been tested in human subjects in clinical trials. However, instead of cytotoxic agents, CXCR4 targeted drugs were mostly used as conditioning regimens. AMD3100, an extensively studied CXCR4 antagonist, was approved to mobilize hematopoietic stem cells for ASCT in NHL patients combined with G-CSF.

For conjugated agents, the liganded drug achieved higher tumor delivery and uptake than the free drug [360, 361]. T22-AUR is an auristatin E nanoconjugate that selectively targets CXCR4-overexpressing DLBCL cells. The cytotoxic effect of T22-AUR to CXCR4+ cells is significantly higher than free auristatin E since the CXCR4-dependent internalization of the conjugates facilitates...
the binding of auristatin E to tubulin, where auristatin E induces cell death. The use of T22-AUR in DLBCL xenograft reduced the dissemination of tumor cells into bone marrow and the central nervous system [302].

One clinical study was initiated recently to investigate the safety of CXCR4 modified CD19 CAR-T cells in refractory B-cell NHL (NCT04684472). Another preclinical study recruited six patients with heavily pretreated DLBCL. They were administered with CXCR4-directed radioligand therapy in combination with conditioning chemotherapy and allogeneic stem cell transplantation. The regimen was well tolerated, resulting in CR of all-CXCR4+ lymphoma but the appearance of CXCR4-lesions, supporting the use of CXCR4-directed radioligand therapy as a conditioning regimen [303].

In all, CXCR4 antagonists can reduce tumor burden and the dissemination of lymphoma to organs. However, the use of these regimens is limited to CXCR4+ lymphomas like CXCR4+ disseminated refractory or relapsed DLBCL patients. For a broader spectrum of patients, the combination of CXCR4 antagonist and other therapy (chemotherapy, targeted therapy, or radiotherapy) is needed.

Targeting immune escape

Recurrent mutations associated with immune escape genes in the DHL-BCL6 may suggest that this subtype is a better candidate for immunotherapy than DHL-BCL2. A number of ongoing trials are investigating the monotherapy and combination therapy of anti-PD-1 antibodies in DLBCL. The results of several clinical trials have been published.

In a phase Ib dose-escalation study of nivolumab, the ORR was 36% in R/R DLBCL with most adverse events (80%) under grade 3 [304]. However, in another phase II study, the ORR was lower, 10% and 3% in relapsed patients after or were ineligible for autologous hematopoietic cell transplantation, respectively. It is worth noting that the membranous PD-L1 level of DLBCLs in this study is only 9%, which may contribute to the differences in the two studies [305]. A study of 105 DLBCL patients showed that when the PD-L1 gene is altered, increased PD-L1 protein downregulated HLA expression, activated NF-κB, and higher response to PD-1 blockade (anti-PD-1 antibody pembrolizumab) were observed (NCT01953692) [306]. Another study observed a similar result when treatment naive DLBCL patients were treated with pembrolizumab in combination with R-CHOP. The toxicity was comparable to R-CHOP alone. The ORR was 90% and the CR rate was 77%. Similar to the study above, higher PD-L1 expression was associated with non-GCB subtype and improved PFS and survival [307]. Based on the study above, together with results in primary CNS lymphoma and primary testicular lymphoma [362], B cell lymphomas with PD-L1 amplification, gain or aberration are likely to have a promising response to PD-1 blockade therapy.

Combined regimens for DHL

Although the targeted agents showed good efficacy or potential for the treatment of DHL with monotherapy, combined regimens had been evaluated on DHL patients, or specific clinical trials on DHL patients are ongoing, such as NCT04479267. We summarized therapeutic targets that had been under clinical evaluation with combined regimens, including the status of clinical trials, clinical response rate, adverse events and so on in Table 6. All these clinical trials covered DHL in the inclusion criteria or reported DHL cases in the relevant publications.

Conclusions and future perspectives

Due to lack of effective treatment and late diagnosis, DHL patients are subjected to intensive chemotherapy and poor outcome. To avoid the late diagnosis, the study result supports the performance of the routine FISH test in all DLBCL patients, which considerably improves the outcome of DHL (ST vs RT: 2-year RFS, 38% v 70% and 2-year overall survival, 38% v 74%). At the same time, routine testing identified a cohort of low-risk DHL patients and the lack of benefit from intensive immunotherapy [28]. Independent research further stratifies DHL into high-risk and low-risk (DHLT + SIG) subgroups, suggesting tremendous heterogeneity lies in the DHL cohort [26]. However, despite the satisfactory efficacy of standard R-CHOP in low-risk DHL, the poor outcome of high-risk DHL remains a challenge, while dose-adjusted intensive regimens become appropriate induction options for most patients with double-hit lymphoma in clinical practice.

To facilitate risk stratification and treatment selection, approaches have been applied to classify DLBCL into different subgroups. Based on cell-of-origin, DLBCLs can be categorized into GCB and non-GCB types, which further include ABC DLBCL and unclassifiable DLBCL. These subgroups differ in biological features, clinical outcomes, and treatment response. For instance, GCB-DLBCL tends to present genetic alterations in the PI3K pathway, which are related to “tonic” BCR signaling, while ABC-DLBCL was observed to harbor mutations characterized as chronic active BCR signaling [143, 371]. Hence, this fundamental divergence contributes to the different responses of DLBCL subtypes to NF-κB pathway inhibition [327]. Similarly, high sensitivity to EZH2 inhibitors was also observed in DLBCLs with hyper-H3K27me3 status, which is closely related to the GCB cohort [372].
Table 6: Therapeutic targets that had been under clinical evaluation for DHL with combined regimens

| Target | Agent | Therapeutics | Stage | Status | N* | Clinical response | Adverse events | References |
|--------|-------|--------------|-------|--------|----|------------------|---------------|------------|
| BCL2   | Venetoclax | + DA-EPOCH-R | Phase II/III (high-grade B-cell lymphomas, including DHL) | Suspended (2019–2028) | – | No result posted | No result posted | NCT03984448 |
|        |        |             | Phase I (aggressive B-Cell Lymphomas, including DHL) | Active, not recruiting (2017–2021) | 31 | ORR: 96-7% (95% CI 82.8–99-9); complete response: 28 (93.3% [77-9–99-2]) of 30; partial response: 1 (3.3% [0-1–17-2]) | Grade 3–4 adverse events: cytopenias (28 [93%] of 30 patients), febrile neutropenia occurred in 19 (63%) patients. Grade 3–4 non-haematological adverse events included hypophosphataemia (n = 10), hypokalaemia (n = 7), and hyperglycaemia (n = 5). Serious adverse events: infection (n = 7) and gastrointestinal toxicities including abdominal pain (n = 3), colonic perforation (n = 1), and small intestinal obstruction (n = 1) | NCT03036904 [363] |
| Proteasome | Bortezomib | + Cyclophosphamide, Dexamethasone, vincristine sulfate liposome | Phase II (r/r ALL, LL, Burkitt Lymphoma, DHL) | Recruiting (2017–2026) | – | No result posted | No result posted | NCT03136146 |
|        |        | + R-CHOP or RB-CHOP | Phase III (DLBCL and other B cell lymphomas, including DHL) | Completed (2011–2015) | 1132 (8 DHL) | Clinical response (DHL): + R-CHOP: 30-months PFS, 38.9%; + RB-CHOP: 30-months PFS, 58.8%; 30-months OS; DHL:DEL:DLBCL, 38-9% vs 61-5% vs75-8% | Most common AEs: Neutropenia, thrombocytopenia, and neuropathy | NCT01324596 [364] |
| CDS2   | Alemtuzumab | + Cyclophosphamide | Phase I (aggressive lymphoma, including DHL) | Terminated (slow accrual) | 3 | No result posted | No result posted | NCT03132584 |
| CD79B  | Polatuzumab Vedotin | + R-CHOP or R-CHP | Phase II (DHL, THL) | Recruiting (2020–2022) | – | No result posted | No result posted | NCT04479267 |
| Target | Agent | Therapeutics | Stage | Status | N<sup>a</sup> | Clinical response | Adverse events | References |
|--------|-------|--------------|-------|--------|-------------|------------------|-----------------|------------|
| HDAC   | Tucidinostat | + BEAC | Phase II (aggressive lymphoma, including DHL) | Active, not recruiting (2018–2021) | 69 | No result posted | No result posted | NCT03629873 |
|        | Fimepinostat | Monotherapy, or + rituximab | Phase I (r/r DLBCL, HGBL, including DHL) | Completed (2012–2020) | 106<sup>a</sup> | Monotherapy: OR 71%, mDOR 13.6 months, mPFS 21.8 months; + rituximab: OR 50%, ORR 64% | Most common adverse events: diarrhea [21 (57%)], thrombocytopenia [20 (54%)], fatigue [15 (41%)], nausea [14 (38%)], constipation [9 (24%)], vomiting [9 (24%)], and neutropenia [8 (22%)]; Grade ≥ 3 adverse events: patients, thrombocytopenia [12 (32%)], neutropenia [6 (16%)], anemia [2 (5%)], diarrhea [2 (5%)], and fatigue [2 (5%)]; | NCT01742988 [203, 365] |
|        | Chidamide | + ChICGB and auto-SCT | Phase II (r/r DLBCL) | Completed (2017–2021) | 93 (2 DHL) | Clinical response: DHL DLBCL: 8%; 4-year PFS 90.0%, 4-year OS 96.8% | Most frequent AEs: Mucositis (43.8%), dermatitis (33.3%), transaminase elevation (43.8%); | NCT03151876 [266] |
| CD3/CD20 | Epcomtamab | + BR or R-GemOx | Phase III (r/r DLBCL, DHL/THL, FL grade 3B) | Recruiting (2021–2024) | – | No result posted | No result posted | NCT04628494 |
| PD-I   | Nivolumab | + DA-EPOCH-R | Phase II (DHL/THL-HGBL) | Recruiting (2018–2026) | – | No result posted | No result posted | NCT03620578 |
|        | Pembrolizumab | + DPX-Survivac, Cyclophosphamide | Phase II (r/r DLBCL, HGBL, including DHL) | Active, not recruiting (2018–2022) | 25 | No result posted | No result posted | NCT03349450 |
| CRBN   | Lenalidomide | + DA-EPOCH-R | Phase II (lymphoma including DLBCL) | Active, not recruiting (2014–2022) | 15 (5 DHL) | Clinical response: 13 CRs (87%), 1 PR (7%), and 1 case of PD (7%); 2-year OS rate 87% and PFS rate 87% | Most common AEs: thromboembolism (4 patients, 27%) and hypokalemia (2 patients, 13%); SAEs: | NCT02213913 [292] |
Table 6 (continued)

| Target | Agent | Therapeutics | Stage | Status | \(N^a\) | Clinical response | Adverse events | References |
|--------|-------|--------------|-------|--------|---------|------------------|----------------|------------|
| DNMT1/2 | Azacitidine | + R-miniCHOP | Phase II/III (DLBCL, Grade 3B FL, DHL/ THL-HGBL) | Recruiting (2021–2025) | – | No result posted | No result posted | NCT04799275 [367] |
|        |       | + R-CHOP | Phase I (DLBCL FL, or Transformed lymphoma) | Completed (2015–2020) | 59 (2 DHL, 1THL) | Dosage: 100-300 mg daily | Clinical response: ORR, 94.9%; CR, 88.1%; estimated 1-year PFS, 84.1%; estimated 2-PFS, 78.6% | MTD was not reached; 2 DLTs Most common grade 3/4 toxicities: Neutropenia (62.7%) and febrile neutropenia (25.4%) | NCT02343536 [368] |
| XPO1 | Selinexor | + R-CHOP | Phase I/II (r/r DLBCL, DHL) | Recruiting (2017–2023) | 12<sup>b</sup> | Dosage: 60/80 mg daily | Clinical response: CR, 80%; PR, 10% | Most common AEs: nausea (100%), fatigue (67%), skin/nail changes (58%), vomiting (42%), dizziness (42%), sinus congestion (42%), and constipation (42%) | NCT03147885 [369] |
|        | Choline Salicylate | + R-CHOP | Phase I (DLBCL, MCL, DHL) | Recruiting (2021–2024) | – | No result posted | No result posted | NCT04640779 |
|        | + RICE | Phase I (aggressive B-Cell Lymphoma, including DHL) | Active, not recruiting (2015–2021) | 22 | No result posted | No result posted | NCT02471911 |
| mTOR | Everolimus | Maintenance therapy with Rituximab | Phase II (Lymphomas) | Completed (2018–2021) | 56 (1 DHL) | 30 month OS: 93%; overall median EFS: 36.4 months; 30 months EFS: 58% | Most frequent AEs: grade 3/4 neutropenia (61.2%), hyperglycemia (18.4%), hypertriglyceridermia (18.4%), thrombocytopenia (16.3%), and anemia (8.2%) | NCT01665768 [370] |

<sup>a</sup> Actual cases or reported cases

<sup>b</sup> No DHL case was reported in the publication
Considering heterogeneity in the DLBCL group, we aim to link distinct genetic events to different DLBCL subgroups, i.e. DHL-BCL2 and DHL-BCL6. After extensive literature, we summarized unique genetic events encompassed in the DHL subtypes. We further collected potential agents targeting these abnormalities, hopefully providing insights into the treatment of DHL. However, this review has certain limitations. Owing to the dominant proportion in DHL and close coincidence with GCB DLBCL, mutations and treatment strategies concerning the DHL-BCL2 cohort are far more elaborate than the DHL-BCL6, which was the minority of DHL with a mixed composition of GCB, ABC, and unclassifiable DLBCLs. More studies and investigations should be done to this subtype, as the incidence of DHL-BCL6 in east Asia is considerable (comparison of two centers: South China: DHL-BCL2 (37%), DHL-BCL6 (63%) [141] vs North American: DHL-BCL2 (87%), DHL-BCL6 (23%) [32].

Although alteration of some pathways was repeated spotted in DHL, agents targeting corresponding proteins or pathways were rarely tested in DLBCLs or yielded unsatisfactory results. As more studies highlight the unique signaling in DHL, novel agents or therapeutic strategies, like CAR-T and CAR-NK, can be tested to accelerate treatment development for these patients.

Abbreviations
ARID1A: AT-rich interaction domain 1A; AKTDA: Activation-induced cytidine deaminase; ASCT: Autologous stem cell transplant; BAK: BCL2 homologous antagonist killer; BAX: BCL2-associated X protein; BCR: Breakpoint cluster region protein; BET: Bromodomain and extraterminal protein; BFL: BCL2-related protein A1; BIRC5: Baculoviral IAP repeat containing 5; BRD4: Bromodomain containing 4 protein; BTK: Bruton's tyrosine kinase; CAR-T: Chimeric antigen receptor T-cell; CD4/6: Cyclin dependent kinase 4 and 6; CHK2: Checkpoint kinase 2; CR: Complete response; CRBN: Cereblon; CREEBP: CAM response element-binding protein; CXCR4: C-X-C motif chemokine receptor 4; DL: Double-expressor lymphoma; DHL: Double-hit lymphoma; DLBCL: Diffuse large B-cell lymphoma; DSS: Disease-specific survival; EB1: Early B cell factor 1; EFS: Event-free survival; ERK: Extracellular signal-regulated kinase; EZH2: Enhancer of zeste homolog 2; FAS: Fas cell surface death receptor; FISH: Fluorescence in situ hybridization; FOXO1: Forkhead box O1; FL3: Fms related receptor tyrosine kinase 3; GCB: Germinal center B-cell like; GEP: Gene expression profile; GNA13: G-Protein subunit alpha 13; HES1: Hes family BHLH transcription factor 1; HLA-DMB: Major histocompatibility complex, class II, DM beta; HVCN1: Hydrogen voltage gated channel 1; IAP2: Inhibition of apoptosis protein 2; JAK: Janus kinase; KITD2: Lyn tyrosine transferase 2D; MCL1: Induced myeloid leukemia cell differentiation protein; MEF2B: Myocyte enhancer factor 2B; mTOR: Mammalian target of rapamycin; MYC: MYC protooncogene; NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells; NHL: Non-Hodgkin's lymphoma; NMT: N-myristoyltransferase; OCT2: Octamer-binding protein 2; ORR: Overall response rate; OS: Overall survival; PFS: Progression-free survival; PI3K: Phosphoinositide 3-kinase; PIK3R1: Phosphoinositide-3-kinase regulatory subunit 1; PIK3: Protein kinase C; POU2F2: POU class 2 homeobox 2; PTEN: Phosphatase and tensin homolog; PUM1: Pololike kinase 1; REL: Proto-oncogene c-rel; RFS: Relapse-free survival; R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-DA-EPOCH: Rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; R-Hyper-CVAD: Rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with cytarabine plus methotrexate; R-CODOX-M/IVAC: Rituximab, cyclophosphamide, vincristine, doxorubicin, methotrexate/ ifosfamide, etopooside, cytarabine, STAT: Signal transducer and activator of transcription; SMAC: Second mitochondria-derived activator of caspase; SRSF2: Serine/arginine-rich splicing factor 2; SPTP: Sphingosine-1-phosphate receptor 2; SYK: Spleen associated tyrosine kinase; TEB: Transcription elongation factor b; TGFβ: Transforming growth factor beta; THL: Triple-hit lymphoma; TNFRSF14: TNF receptor superfamily member 14; TNFR1: Tumor necrosis factor receptor 1; TYK2: Tyrosine kinase 2; XPO1: Exportin 1.

Acknowledgements
Not applicable.

Authors’ contributions
Y. Z., J. C., M. W., Y. G. and Y. X. contributed to the collection of references and manuscript preparation. X. D. and H. Y. contributed to the plan and modification of the manuscript. All authors read and approved the final manuscript.

Funding
The study was supported by the National Natural Science Foundation of China (81973172, 82003579), Natural Science Foundation of Zhejiang Province (LRZ1H300003, LQ21H300005), Science and Technology Program of Traditional Chinese Medicine, Zhejiang (2021ZB036).

Availability of data and materials
The material supporting the conclusion of this review has been included within the article.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
The content of this manuscript has not been previously published and is not under consideration for publication elsewhere. All the authors are aware of and agree with the content of the paper and are listed as co-authors of the paper.

Competing interests
The authors declare no conflict of interests.

Author details
1 Department of Lymphoma, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, People’s Republic of China. 2 Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People’s Republic of China. 3 Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou, People’s Republic of China. 4 Department of Pathology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, People’s Republic of China. 5 Cancer Center, Zhejiang University, Hangzhou, People’s Republic of China.

Received: 31 December 2021 Accepted: 7 March 2022
Published online: 18 March 2022

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2020. CA Cancer J Clin. 2020;70(1):7–30.
2. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(28):3452–9.
3. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmi M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.

4. Swerdlow SH. Diagnosis of "double hit" diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematol Am Soc Hematol Educ Program. 2014;2014(1):90–9.

5. Sesques P, Johnson NA. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood. 2017;129(3):280–8.

6. Ma Z, Niu J, Cao Y, Pang X, Zheng W, Li X. Clinical significance of double-hit and double-expression lymphomas. J Clin Pathol. 2020;73(3):126–38.

7. Merron B, Davies A. Double hit lymphoma: How do we define it and how do we treat it? Best Pract Res Clin Haematol. 2018;31(3):233–40.

8. Copie-Bergman C, Guillere-Dantignes P, Baia M, Briere J, Delarue R, Canioni D, Salles G, Parens M, Belhadj K, Fabiani B, et al. MYC-G rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015;126(22):2466–74.

9. McPhail ED, Maurer M, Macon WR, Feldman AL, Kurtin PJ, Ketterling RR, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, et al. Superior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC-G rearrangements. Haematologica. 2018;103(10):1899–907.

10. Pedersen MO, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, Nielsen SL, Klausen TW, Norgaard P. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC-or double-hit MYC/BCL2 translocations. Eur J Haematol. 2014;92(1):42–8.

11. Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn DJ, Cerhan JR, Ansell SM, Porrata LF, et al. MYC translocation partner gene determines survival of patients identified via routine vs selective testing for MYC rearrangement. Blood. 2019;133(1):1607–1607.

12. Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Russhicht C, Tang J, Thomas N, Slack GW, et al. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(3):190–211.

13. Frosch ZAK, Landsburg DJ. Molecular risk stratification in aggressive B-cell lymphomas. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(18):2049–57.

14. Frosch ZAK, Dwivedy Nasta S, Schuster SJ, Svoboda J, Barta SK, Gerson JN, Chong EA, Ayers EC, Rhodes JM, Koike A, et al. Outcomes for double hit lymphoma patients identified via routine vs selective testing for MYC rearrangement. Blood. 2019;134(Supp 1):1607–1607.

15. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–61.

16. Oki Y, Noorani M, Lin P, Davis RE, Neeapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, et al. Double hit lymphoma: the MD Anderson cancer center clinical experience. Br J Haematol. 2014;166(6):891–901.

17. Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170(4):504–14.

18. D’Angelo CR, Hanel W, Chen Y, Yu M, Yang D, Guo L, Karmali R, Burkart M, Ciccossanti C, David K, et al. Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: a multi-center analysis. Hematol Oncol. 2021;39(4):473–82.

19. Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Meledes LJ, et al. Outcomes of patients with molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135(20):1759–71.
double-hit lymphoma who achieve first complete remission. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(20):2260–7.

37. Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, Sehn LH, Abou-Mosur Y, Barnett MJ, Broady RC, et al. Outcome of patients with non-hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M/IVAC with rituximab followed by hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15(6):341–8.

38. Li S, Lin P, Fayad LE, Lennard PA, Miranda RN, Yin CC, Lin E, Medeiros LJ. B-cell lymphomas with MYC/8q24 rearrangements and IgH@BCL2 (14q32-18q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol Off J US Can Acad Pathol. 2012;25(1):145–56.

39. Laude MC, Lebras L, Sesques P, Ghesquieres H, Favre S, Bouabdallah K, Crozier C, Guieze R, Dreu La Rochelle L, Gyan E, et al. First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study. Am J Hematol. 2021;96(3):92–11.

40. Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Coban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, et al. Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG 59704. Br J Haematol. 2016;174(5):686–91.

41. Huang W, Medeiros LJ, Lin P, Wang W, Tang G, Khoury J, Konoplev S, Yin CC, Xu J, Okie Y, et al. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. Mod Pathol. 2018;31(9):1470–8.

42. Zhang J, Vlasevska S, Mo T, Tang H, Basso K, et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma. Cancer Discov. 2017;7(3):322–37.

43. Zhang J, Dominguez-Sola D, Hussein S, Lee JE, Holmes AB, Bansal M, Vlasevska S, Mo T, Tang H, Basso K, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21(10):1190–8.

44. Brescia P, Schneider C, Holmes AB, Shen Q, Hussein S, Pasqualucci L, Basso K, Dalla-Favera R. MEF2B instructs germinal center development and acts as an oncogene in B cell lymphomagenesis. Cancer Cell. 2018;34(3):453–465.e459.

45. Béguelin C, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Lee CH, Melchers M, Wang H, et al. First-line treatment of double-hit and triple-hit lymphomas after R-CHOP with and without consolidative autologous stem cell transplantation: survival and tolerance data from a retrospective multicenter French study. Am J Hematol. 2021;96(3):302–11.

46. Amini RH, Schissel MS, Anderson J, Fox1 directly regulates the transcription of recombination-activating genes during B cell development. Nat Immunol. 2008;9(6):613–22.

47. Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJ, Mungall AJ, Zhao Y, Schein J, Steidl C, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121(18):3666–74.

48. Xie L, Ushmorov A, Leithauser F, Guan H, Steidl C, Farbinger J, Pelzer C, Vogel MJ, Maier HJ, Gascoyne RD, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. 2012;119(15):3503–11.

49. Sanders C, Chu VT, Yasuda T, Franklin A, Graf R, Calado DP, Li S, Imami K, Selbach M, Di Virgilio M, et al. PI3 kinase and FOXO1 transcription factor activity differentially control B cells in the germinal center light and dark zones. Immunity. 2015;43(6):1075–86.

50. Szydlowski M, Kilkicz P, Sewastianik T, Jablonska E, Bialekpotowicz E, Gorniak P, Polak A, Markowsicz S, Nowak E, Grygoryowicz MA, et al. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Blood. 2016;127(6):739–48.

51. Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, et al. Genetic Landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin Cancer Res. 2016;22(9):2290–300.

52. Ushmorov A, Wirth T. FOXO1 in B-cell lymphomogenesis and B cell neoplasia. Semin Cancer Biol. 2018;50:132–41.

53. Hodson DJ, Shaffer AL, Xiao W, Wright GW, Schmitz R, Phelan JD, Yang Y, Webster DE, Rui L, Kohlhammer H, et al. Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. Proc Natl Acad Sci USA. 2016;113(14):E2093-2094.

54. Karnowski A, Chevrier S, Belz GT, Mount A, Emslie D, D’Costa K, Tarlinton DM, Kallies A, Corcoran LM, and B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. J Exp Med. 2012;209(1):2049–64.

55. Corcoran LM, Emslie D, Kridel R, Boyle M, Slack GW, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, et al. Genetic Landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin Cancer Res. 2016;22(9):2290–300.

56. Ushmorov A, Wirth T. FOXO1 in B-cell lymphomogenesis and B cell neoplasia. Semin Cancer Biol. 2018;50:132–41.
of IP3-receptor-mediated Ca2+-signaling and apoptosis by the BH4 domain of BCL2 versus Bcl-Xl. Cell Death Differ. 2012;19(2):295–309.

74. Ding J, Zhang Z, Roberts GJ, Falcone M, Miao Y, Shao Y, Zhang XC, Andrews DW, Lin J. BCL2 and Bax interact via the BH1-3 groove-BH3 motif interface and a novel interface involving the BH4 motif. J Biol Chem. 2012;287(51):38459–63.

75. Frequent V, Rieger M, Carolis C, Garcia-Barchino MJ, Martinez-Climent JA. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood. 2014;123(26):4111–9.

76. Guegan JP, Ginestier C, Charafe-Jauffret E, Ducret T, Quignard JF, Vacher P, Legembre P. CD95/Fas and metastatic disease: What does not kill you makes you stronger. Semin Cancer Biol. 2020;60:121–31.

77. Takahashi H, Feuerhake F, Kikut J, Monti S, Dal Cin P, Neuberg D, Auster JC, Shippan MA. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res. 2006;12(11 Pt 1):3265–71.

78. Razzaghi R, Agarwal S, Kotlov N, Plotnikova O, Nomie K, Huang DW, Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012;48(4):491–509.

79. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13(5):343–57.

80. Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, Jiang M, Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin RD, Sahasrabuddhe AA, Chen X, Chung F, Velusamy T, Lim MS, Elenitoba-Johnson KS, Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Deng Y, Chen X, Huang C, Chen G, Chen F, Lu J, Shi X, He C, Zeng Z, Qiu Y, et al. EZH2 catalytic activity, to increase H3K27 trimethylation. Blood. 2015;115(6):2419–52.

81. Hashwah H, Schmid CA, Kasser S, Bertram K, Stelling A, Manz MG, Muller A. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. Proc Natl Acad Sci U S A. 2017;114(36):9701–6.

82. Chu J, Wang T, Huang CX, Fang Y, Cheng S, Sun XJ, Liu F, Huang JY, et al. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct Target Ther. 2021;6(1):10.

83. Cerchietti LC, Hatzi K, Calsada-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shakhnovich R, Cole PA, et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov. 2017;7(11):38–53.

84. Garcia-Ramirez I, Tadros S, Gonzalez-Herrero J, Martin-Lorenzo A, Rodriguez-Gonzalez H, Moore D, Rzuca-Riano L, Blanco O, Alonso-Lopez D, Rivas JL, et al. CREBBP loss cooperates with BCL2 overexpression to promote lymphoma in mice. Blood. 2012;119(18):2645–56.

85. Komeno Y, Huang JS, Qiu J, Lin L, Xu Y, Zhou Y, Chen L, Monterroza DD, Cai J, Wang J, et al. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies. Exp Hematol. 2019;79:35–46.

86. Scialdone A, Khazaiei S, Hasni MS, Lennartsson A, Gullberg U, Drott K, Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies. Exp Hematol. 2019;79:35–46.

87. Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shakhnovich R, Cole PA, et al. CREBBP loss cooperates with BCL2 overexpression to promote lymphoma in mice. Blood. 2012;119(18):2645–56.

88. Scialdone A, Khazaiei S, Hasni MS, Lennartsson A, Gullberg U, Drott K, Scialdone A, Khazaiei S, Hasni MS, Lennartsson A, Gullberg U, Drott K, Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies. Exp Hematol. 2019;79:35–46.

89. Cerchietti LC, Hatzi K, Calsada-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shakhnovich R, Cole PA, et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov. 2017;7(11):38–53.

90. Garcia-Ramirez I, Tadros S, Gonzalez-Herrero J, Martin-Lorenzo A, Rodriguez-Gonzalez H, Moore D, Rzuca-Riano L, Blanco O, Alonso-Lopez D, Rivas JL, et al. CREBBP loss cooperates with BCL2 overexpression to promote lymphoma in mice. Blood. 2012;119(18):2645–56.

91. Hashwah H, Schmid CA, Kasser S, Bertram K, Stelling A, Manz MG, Muller A. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. Proc Natl Acad Sci U S A. 2017;114(36):9701–6.

92. Chu J, Wang T, Huang CX, Fang Y, Cheng S, Sun XJ, Liu F, Huang JY, et al. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct Target Ther. 2021;6(1):10.

93. Cerchietti LC, Hatzi K, Calsada-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shakhnovich R, Cole PA, et al. CREBBP loss cooperates with BCL2 overexpression to promote lymphoma in mice. Blood. 2012;119(18):2645–56.

94. Scialdone A, Khazaiei S, Hasni MS, Lennartsson A, Gullberg U, Drott K, Scialdone A, Khazaiei S, Hasni MS, Lennartsson A, Gullberg U, Drott K, Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies. Exp Hematol. 2019;79:35–46.

95. Cerchietti LC, Hatzi K, Calsada-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shakhnovich R, Cole PA, et al. CREBBP loss cooperates with BCL2 overexpression to promote lymphoma in mice. Blood. 2012;119(18):2645–56.

96. Scialdone A, Khazaiei S, Hasni MS, Lennartsson A, Gullberg U, Drott K, Scialdone A, Khazaiei S, Hasni MS, Lennartsson A, Gullberg U, Drott K, Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies. Exp Hematol. 2019;79:35–46.
110. Havranek O, Xu J, Kohrer S, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Man Chun Ma J, Westin JR, et al. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood. 2017;130(8):995–1006.

111. Kober-Hasslacher M, Schmidt-Supprian M. The unsolved puzzle of c-Rel in B cell lymphoma. Cancers (Basel). 2019;11(7).

112. Houldsworth J, Mathew S, Rao PH, Dykinson K,Louie DC, Parsa N, Offit K, Chaganti RS. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood. 1996;87(1):25–9.

113. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, et al. NFkappaB activity, function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood. 2005;106(4):1392–9.

114. Houldsworth J, Olsén AB, Cattoretti G, Donnelly GB, Teruya-Feldstein J, Qin J, Palaisanmis N, Shen Y, Dykinson K, Petkahl M, et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood. 2004;103(5):1862–8.

115. Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, Visco C, Zhang M, Montes-Moreno S, Dybkær K, et al. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015;6(27):23157–80.

116. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12(3):229–43.

117. Pfeifer M, Graus-Porta D, Lenze D, Wenzel SS, Wolf A, Woolf-Wulf B, Dietze K, Nogai H, Storkel S, Madle H, et al. PTEN loss defines a P53K3/AKT pathway-dependent germinial center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110(30):12420–25.

118. Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signal-processing in B cells. Nat Rev Immunol. 2009;9(1):47–55.

119. Ritz O, Guiter C, Dorsch K, Deaths F, Wegener S, Jouault H, Yildiz M, Li H, Bernard D, Amin NA, Ouillette P, Jones S, Saiya-Cork K, Paradis J, Cattoretti G, et al. Enhanced activation of an amino-terminally truncated isoform of the voltage-gated sodium channel Na1.5 in malignant B cells. Proc Natl Acad Sci USA. 2014;111(50):18078–83.

120. Mintz MA, Felce JH, Chou MY, Maya V, Xu Y, Shiu JW, et al. The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis. Immunity. 2019;51(2):310–23.

121. Boice M, Salloum D, Mounicol F, Sanghvi V, Amin R, Orciolo E, Jiang M, Mottok A, Denis-Lagache N, Cirriolo G, et al. Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. Cell. 2016;167(2):405–18.

122. Costello RT, Mallet F, Barbarat B, De Coiletra JMS, Sainty D, Sweet RW, Trunech A, Olive D. Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and cell death. J Biol Chem. 2000;275(3):1419–24.

123. Green JA, Suzuki K, Cho B, Willson LD, Palmer D, Allen CD, Schmidt TH, Xu Y, Proia RL, Coughlin SR, et al. The sphingosine 1-phosphate receptor S1P2(+) maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat Immunol. 2011;12(7):672–80.

124. Muppidi JR, Schmitz R, Green JA, Xiao W, Larsen AB, Braun SE, et al. Xu J, Xu Y, Rosenwald A, Ott G, et al. Loss of signalling via Galphalalpha13 in germinal center-cell-derived lymphomas. Nature. 2014;516(7530):254–6.

125. Cattoretti G, Mandelbaum J, Lee N, Chen H, Mahler AH, Mahler AM, Chabamura S, Dallavera R, Pasqualucci L, Maclennan AJ. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res. 2009;69(22):8866–92.

126. Stelling A, Hashiwaha H, Bertram K, Manz MG, Tzankov A, Muller A. The tumor suppressive TGF-beta/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphomas. Blood. 2018;131(20):2235–46.

127. Xia Z, Zhang X, Liu P, Zhang R, Huang Z, Li D, Xiao W, Wu M, Ning N, Zhang Q, et al. GNA13 regulates BCL2 expression and the sensitivity of GBM-DLBCL cells to BCL2 inhibitors in a p53 mutation-dependent manner. Cell Death Dis. 2021;12(1):54.

128. Zhang J, Weng Z, Huang Y, Li M, Wang F, Wang Y, Rao H. High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 translocations. Leuk Lymphoma. 2019;61(6):179–85.

129. Gaidarkis O, Xu Y. Transcription activity is required for p53-dependent tumor suppression. Oncogene. 2009;28(49):4397–401.

130. Song JY, Perry AM, Herrera AF, Chen L, Skrabek P, Nasr MR, Ottesen RA, Nikowitz J, Bedell V, Murata-Collins J, et al. Double-hit signature with del17p is recurrent in diffuse large B-cell lymphoma. Cancer Res. 2021;81(16):4671–80.

131. Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013;122(7):1256–65.

132. Nairismagi ML, Tan J, Lim JQ, Nagarajan S, Ng CC, Rajasegaran V, Huang D, Lim WK, LaCasce AS, Wijaya GC, et al. JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epithelioid trophoblastic intestinal T-cell lymphoma. Leukemia. 2016;30(6):1311–9.
factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling. Blood. 2017;129(4):460–72.

149. Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL, 3rd, Cenbelli M, Wang JQ, Schmizt R, et al. A multiprotein supercomplex controlling oncogenic signaling in lymphoma. Nature. 2018;560(7218):387–91.

150. Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguilar RC. MicroRNAs mir-1215a and mir-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA. 2012;109(20):7865–70.

151. Mei ZZ, Chen XY, Hu SW, Wang N, Ou XL, Wang J, Luo HH, Liu J, Jiang Y. Kelch-like protein 21 (KLHL21) targets ikappaB kinase-beta to regulate nuclear factor kappa-light chain enhancer of activated B cells (NF-κappaB) signaling negatively. J Biol Chem. 2016;291(35):18176–89.

152. Courtehoux T, Enchev RJ, Lampert F, Gerecz J, Beck J, Picotti P, Sumara I, Peter M. Cortical dynamics during cell motility are regulated by CRL3(KLHL21) E3 ubiquitin ligase. Nat Chem. 2016;8(1):1260–8.

153. Li L, Zhang W, Liu Y, Liu X, Cai L, Kang J, Zhang Y, Chen W, Dong C, Saito T, Chiba S, Ichikawa M, Kunisato A, Asai T, Shimizu K, Yamaguchi T, Lee SY, Kumano K, Nakazaki K, Sanada M, Matsumoto A, Yamamoto G, Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, Skrabs C, Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Jethwa A, Slabicki M, Hullein J, Jentzsch M, Dalal V, Rabe S, Wagner L, Xu-Monette ZY, Zhang S, Li X, Manyam GC, Wang XX, Xia Y, Visco C, Peters M, Mauffret O, Avril MF, Chompret A, Lenoir GM, et al. Functional, expression changes, and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci. 2009;100(5):920–6.

154. Zhang X, Shi Y, Wang Y, Lai Q, Luo T, Zhao J, Ren G, Li W, Pan H, Ke Y, et al. The truncated mutation of Notch2 enhances cell proliferation through activating the NF-kappaB signal pathway in the diffuse large B-cell lymphomas. PLoS ONE. 2014;9(10):e108747.

155. de Miranda NF, Georgiou K, Chen L, Wu C, Gao Z, Zaravinos A, Lisboa S, Enblad G, Teixeira MR, Zeng Y, et al. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood. 2014;124(16):2544–53.

156. Meninna L, Pasanen A, Louhimo R, Cervera A, Alkordsi A, Autio M, Taskinen M, Rantavuori V, Karjalainen-Lindsberg ML, Holte H, et al. Del- tex-1 mutations predict poor survival in diffuse large B-cell lymphoma. Haematologica. 2017;102(5):195–8.

157. Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kadier A, Skrabs C, Pirker R. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res. 2002;8(5):729–33.

158. Lee SY, Kumano K, Nakasaki K, Sanada M, Muramatsu A, Yamamoto G, Nannya Y, Suzuki R, Ota S, Ota Y, et al. Gain-offunction mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cell. 2006;200(6):262–75.

159. Jethwa A, Slabicki M, Hullein J, Jentzsch M, Dalal V, Rabe S, Wagner L, Wulder A, Tzapounidis S, Guelen S, Uehara S, et al. CCR4 inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011;20(3):278–90.

160. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovska S, Torrejon D, Abril-Rodriguez G, Sandoval S, Barthly L, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2013;369(18):1819–29.

161. Georgiou K, Chen L, Berglund M, Ren W, de Miranda NF, Lisboa S, Fang-gao M, Zhu S, Hou Y, Wu K, et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood. 2016;127(24):3026–34.

162. Song MK, Park BB, Uh JH. Understanding immune evasion and therapeutically targeting associated with PD-L1/PD-L1 pathway in diffuse large B-cell lymphoma. Int J Mol Sci. 2019;20(6).

163. Zabel BA, Lewen S, Berahovich RD, Jaen JC, Schall TJ. The novel receptor molecule CXCR7 regulates trans-endothelial migration of cancer cells. Mol Cancer. 2011;10:73.

164. Pansy K, Feichtinger J, Ehart B, Uhl B, Sedey M, Roula D, Pursche B, Wolf A, Zoidl M, Steiberne E et al. The CXCR4-CXCL12 axis is of prognostic relevance in DLBCL and its antagonists exert pro-apoptotic effects in vitro. Int J Mol Sci. 2019;20(19).

165. Moreno MJ, Bosch R, Dieguez-Gonzalez R, Novelli S, Mozos A, Gallardo A, Pavaon MA, Cespedes MV, Granena A, Alcoveca M, et al. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. J Pathol. 2015;233(3):445–53.

166. Durr C, Pfeifer D, Claus R, Schmitt-Graeff A, Gerlach U, Graser R, Kruger S, Gerbitz A, Negrin RS, Finkle J, et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cancer cells. Cancer Res. 2010;70(24):1071–80.

167. Peled A, Klein S, Beider K, Burger JA, Abraham M. Role of CXCL12 and CXCR4 in the pathogenesis of hematologic malignancies. Cytokine. 2018;109:11–6.

168. Kim JH, Kim WS, Ryu KY, Kim SJ, Park C. CXCR4 can induce PI3Kdelta inhibitor resistance in ABC DLBCL. Blood Cancer J. 2018;8(2):23.

169. Treon SP, Xu L, Guererra ML, Jimenez C, Hunter 2R, Liu X, Demos M, Gustine J, Chan G, Munshi M, et al. Genomic landscape of Waldenstrom macroglobulinemia and its impact on treatment strategies. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(11):1198–208.

170. Ennishi D, Healy S, Bashashati A, Saberi S, Hother C, Mottok A, Chan FC, Chong L, Abraham L, Kriedel R, et al. TMEM106A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nat Med. 2020;26(4):577–88.

171. Drygin D, Lin A, Bliesath J, Ho CB, O’Brien SE, Proffitt C, Omori M, Haddad M, Schwabe MK, Siddiqui-Jain A, et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 2011;71(4):1418–30.

172. Webb MS, Tortora N, Cremese M, Kozlowska H, Blaquiere M, Devine DV, Kornbrust DJ. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev. 2001;11(3):153–63.
186. de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018;29(9):1952–8.

187. Monschhauser F, Feugier P, Flinn M, Gasiorowski R, Greil R, Illes A, John- son NA, Larrouche JF, Lugtenburg PJ, Pattin C, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600–9.

188. Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, Stachura J, Letai A, Lawton LN, Chapuy B, et al. Targeted inhibition of PI3KAlphadelta is synergistic with BCL2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133(1):70–80.

189. Sasi BK, Martines C, Kerse A, Forno F, Kallian H, Fazio R, Greil R, Illes A, John- sas BK, Martines C, Xerxa E, Porro F, Kalkan H, Fazio R, Turkalj S, Bojnik E, Cheng C, Wang T, Song Z, Peng L, Gao M, Hermine O, Rousseaux S, Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, Guan X-W, Hua-Qing W, Jia L, Liu F-T. The novel HDAC inhibitor chidamab Lue JK, Prabhu SA, Liu Y, Gonzalez Y, Verma A, Mundi PS, Abshiru N, Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S, van der Jagt RH, Copeland A, Potvin D, Chauhan J, Hu A, Pendleton K, Yap JL, Sabato PE, Jones JW, Perri M, Yu J, Gone E, Kane MA. Disruption of MYC-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074–G5. Oncotarget. 2013;4(6):936–49.

190. Mo H, Henriksson M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Proc Natl Acad Sci USA. 2005;10(16):6344–9.

191. Mo H, Vita M, Crespin M, Henriksson M. Myc overexpression enhances apoptosis induced by small molecules. Cell Cycle. 2006;5(19):2191–4.

192. Neidle S. Quadruplex nucleic acids as novel therapeutic targets. J Med Chem. 2016;59(3):5987–6011.
222. Zhang X, Bi C, Lu T, Zhang W, Yue T, Wang C, Tan T, Zhang X, Huang Y, Lunnung M, et al. Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas. Leukemia. 2020;34(1):138–50.

223. Chu J, Zhang W, Cencic R, O'Connor PBF, Robert F, Devine WG, Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Li W, Wang J, Liu Z, Wang S, Chen Z, Li Z, Zhang M, Zou J, Dong B, Gao J, et al. Targeting c-Myc. JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. Cancer Lett. 2018;419:64–74.

224. Wu Z, Hu Z, Han X, Li Z, Zhu Q, Wang Y, Zheng Q, Yan J. The BET-Brotherhood Interaction Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression. Biomed Pharmaceutical. 2017;9:1575–9.

225. Devaiah BN, Mu J, Akman B, Uppal S, Weissman JD, Cheng D, Baranello Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, Tilly H, Copie-Bergman C. Double-hit DLBCL: should we limit FISH testing? Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding J, Li L, Pongtornpipat P, Tiutan T, Kendrick SL, Park S, Persky DO, Rimsza clanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, Pruncks LM, Puvvada SD, Schatz JH. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia. 2015;29(8):1702–13.

226. Khanova M, Andera L, Braxia J, Svedenka J, Benesova S, Soukup J, Pukova D, Vojtekova D, Jaksik R, Helman K, et al. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Clin Cancer Res Off Am Assoc Cancer Res. 2012;17(11):3304–13.

227. Asparagi I, Meroni A, Battelli S, Fabbri R, Prisco F, Russo G, Provenzale L, Liu L, Qiu Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, Liu Q, S Yang CY, Miller R, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem. 2011;54(8):2714–26.

228. DiPersio JF, Erba HP, Larson RA, Luger SM, Tallman MS, Brill JM, Vuagniaux G, Routts E, Sorenson JM, Zanna C, Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia—results of a phase I dose-escalation study. Clin Lymphoma Myeloma Leuk. 2015;15(7):443–9.

229. Zinngrebe J, Schlichtig F, Kraus JM, Meyer M, Boldrin E, Kestler HA, Meyer LH, Fischer-Posadowsky P, Debattin KM. Biomarker profile for prediction of response to SMAC mimetic monotherapy in pediatric precursor B-cell acute lymphoblastic leukemia. Int J Cancer. 2020;146(11):3219–31.

230. Vaque JP, Martinez N, Batlle-Lopez A, Perez C, Montes-Moreno S, Sanchez-Beato M, Pins MA. B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica. 2014;99(2):222–31.

231. Beauchamp E, Yap MC, Iyer A, Perinpanayagam MA, Gamma JM, Vincent KM, Lakshmanan M, Raju A, Tergaonkar V, Tan SY, et al. Targeting N-myristoylation for therapy of B-cell lymphomas. Nat Commun. 2020;11(1):5348.

232. Lv S, Wen H, Shan X, Li J, Wu Y, Yu X, Huang W, Wei Q. Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXD3. Epigenetics. 2019;14(12):1194–208.

233. Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019;16(8):494–507.

234. Wang G, Chow RD, Zhu L, Bai Z, Ye L, Zhang F, Renauer PA, Dong MB, Dai X, Zhang X, et al. CRISPR-GEMM-pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade. Cancer Discov. 2020;10(12):1323–34.

235. Bereschenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet. 2002;32(4):606–13.

236. Guan XW, Wang HQ, Ban WW, Zhang C, Chen HZ, Liu FT. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20. Cell Death Dis. 2020;11(1):20.

237. Wu SY, Chiang CM. The double-bromodomain-containing chromatin adapter Brd4 and transcriptional regulation. J Biol Chem. 2007;282(18):13141–5.

238. Devaiah BN, Georgone A, Singer DS. Bromodomain 4: a cellular Swiss army knife. J Leukoc Biol. 2016;100(4):679–86.

239. Najafova Z, Tirado-Magallanes R, Subramaniam M, Hossan T, Schmidt G, Nagarajan S, Baumgart SJ, Mishra VK, Hesse E, et al. BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire. Nucleic Acids Res. 2017;45(1):127–41.

240. Ozer HG, El-Gamal D, Powell B, Hing ZA, Blackly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, et al. BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor. Cancer Discov. 2018;8(4):458–77.

241. Vazquez R, Rivero ME, Almodovar-Menendez L, Odone E, Rezai K, Erba E, Panin N, Rinaldi A, Kwee I, Betlemme M, et al. The bromodomain inhibitor OTX005 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Oncotarget. 2017;8(5):5798–613.
Kurniyati K, Kelly JF, Vinogradov E, Robotham A, Tu Y, Wang J, Liu J, Logan SM, Li C. A novel glycan modifies the flagellar filament proteins of the oral bacterium Treponema denticola. Mol Microbiol. 2017;103(1):67–85.

Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017;23(4):493–500.

Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knuston D, Grepp PT, Elawa SF, Sotomayor EM, Gupta M. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):73.

Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov. 2017;16(4):241–63.

Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623–9.

Tamma R, Ingravallo G, Gaudio F, C debuto MA, Millioni E, Robotham A, Tu Y, Wang J, Liu Z, Zhuang Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017;23(4):493–500.

Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knuston D, Grepp PT, Elawa SF, Sotomayor EM, Gupta M. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):73.

Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov. 2017;16(4):241–63.

Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623–9.

Tamma R, Ingravallo G, Gaudio F, C debuto MA, Millioni E, Robotham A, Tu Y, Wang J, Liu Z, Zhuang Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017;23(4):493–500.

Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knuston D, Grepp PT, Elawa SF, Sotomayor EM, Gupta M. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):73.

Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov. 2017;16(4):241–63.

Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623–9.

Tamma R, Ingravallo G, Gaudio F, C debuto MA, Millioni E, Robotham A, Tu Y, Wang J, Liu Z, Zhuang Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017;23(4):493–500.

Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knuston D, Grepp PT, Elawa SF, Sotomayor EM, Gupta M. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):73.

Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov. 2017;16(4):241–63.

Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623–9.

Tamma R, Ingravallo G, Gaudio F, C debuto MA, Millioni E, Robotham A, Tu Y, Wang J, Liu Z, Zhuang Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017;23(4):493–500.

Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knuston D, Grepp PT, Elawa SF, Sotomayor EM, Gupta M. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):73.

Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov. 2017;16(4):241–63.

Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623–9.

Tamma R, Ingravallo G, Gaudio F, C debuto MA, Millioni E, Robotham A, Tu Y, Wang J, Liu Z, Zhuang Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017;23(4):493–500.

Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knuston D, Grepp PT, Elawa SF, Sotomayor EM, Gupta M. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):73.

Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov. 2017;16(4):241–63.

Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623–9.

Tamma R, Ingravallo G, Gaudio F, C debuto MA, Millioni E, Robotham A, Tu Y, Wang J, Liu Z, Zhuang Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017;23(4):493–500.

Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knuston D, Grepp PT, Elawa SF, Sotomayor EM, Gupta M. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):73.
lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood. 2019;134(13):1024–36.

297. Thieblemont C, Tilly H, Gomes da Silva M, Casanovos RO, Frucht C, Monchhauzer F, Haicou C, Lazarovic I, Groniska A, Perrot A, et al. Lena-

lidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line ritux-

imab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(22):2473–81.

298. Jiang L, Sun Y, Wang J, He Q, Chen X, Lan X, Chen J, Dou QP, Shi X, Liu J. Proproteinase 3 has been used as a relevant marker for diagnosis and predicts outcomes in diffuse large B-cell lymphoma. J Exp Clin Cancer Res. 2018;38(1):435.

299. Kasamon YL, Price LSL, Okusanya OO, Richardson NC, Li RJ, Ma L, Wu Dey J, Deckwerth TL, Kerwin WS, Casalini JR, Merrell AJ, Grenley MO, Liu SH, Gu Y, Pascual B, Yan Z, Hallin M, Zhang C, Fan C, Wang W, Lam Falgas A, Pallares V, Unzueta U, Nunez Y, Sierra J, Gallardo A, Alba-Castel-

lon L, Mangues MA, Alamo P, Villaverde A, et al. Specific cytotoxic effect of an auratinan nonconjugate toward CCR4+ diffuse large B-cell lymphoma cells. Int J Nanomed. 2021;16:1869–88.

300. Lappa C, Hanscheid H, Kircher M, Schirbel A, Wunderlich GW, Werner RA, Samnick S, Kotzerke J, Einsle H, Buck AK, et al. Feasibility of CCR4-directed radioligand therapy in patients with diffuse large B-cell lymphoma. J Nucl Med. 2019;60(1):60–4.

301. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millen MM, Cohen AD, Schuster SJ, Lebovic D, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(23):2698–704.

302. Godfrey J, Tumuluru S, Bao R, Leukam M, Venkataraman G, Phillip J, Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell lymphoblastic leukemia/lymphoma. Nat Rev Clin Oncol. 2019;16(10):634–52.

303. Karmali R, Gordon LI. Molecular subtyping in diffuse large B-cell lymphoma: closer to an approach of precision therapy. Curr Treat Options Oncol. 2017;18(2):1–17.

304. Davids MS, Brown JR. Brutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncol. 2014;10(6):957–67.

305. Al-Juhaishi T, McKay J, Sindel A, Yazbeck V. Perspectives on chemotheraphy for the management of double-hit lymphoma. Expert Opin Pharmacother. 2020;21(6):653–61.

306. Suljagic M, Longo PG, Benardo S, Perias E, Leon G, Laurenti L, Eremov DG. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu–TCL1 transgenic mouse model of CLI by blocking antigen-dependent B-cell receptor signaling. Blood. 2010;116(23):4894–905.

307. Choi MY, Kipps TJ. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J. 2012;18(S5):404–10.

308. Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DG, Hellenbach SJ, Pandey A, Sinha U. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmune and B-cell cancer. J Pharmacol Exp Ther. 2014;351(3):538–48.

309. Ma J, Xing W, Coffey G, Dresser K, Lu K, Guo A, Raca G, Pandey A, Cons-

ley P, Yu H, Wang YL, et al. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B-cell lymphoma. Oncotarget. 2015;6(41):43881–96.

310. Chen Y-B, LaCasce AS. Nازtasurin. Expert Opin Investig Drugs. 2008;17(9):934–49.

311. Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma: possible clinical implications and challenges. Mol Pharmacol. 2010;116(2):4894–905.

312. Fech U, Kibo B, Gewies A, Pfander V, Duwel M, Peschel C, Krappmann D, Ruland J. Inhibition of BTK, MALT1 protease activity is selectively toxic for activated B-cell-like diffuse large B cell lymphoma cells. J Exp Med. 2015;206(11):2313–20.

313. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–9.

314. Karmali R, Gordon LI. Molecular subtyping in diffuse large B-cell lymphoma: closer to an approach of precision therapy. Curr Treat Options Oncol. 2017;18(2):11.

315. Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Leno-

dilomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma cells. J Exp Med. 2009;206(11):2313–20.

316. Zhu M. Inhibitory effects of bortezomib in a subcutaneous tumor model of H22 mouse hepatocarcinoma cells. Pathol Res Pract. 2009;215(6):523–38.

317. Salati M, Tarantino V, Maiorana A, Bettelli S, Luminari S. Durable remis-

sion in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy. Hematol Oncol. 2017;35(4):861–3.

318. Cenicse Seval G, Bekas M. The safety of bortezomib for the treatment of multiple myeloma. Expert Opin Drug Saf. 2018;17(9):953–62.

319. Yazebeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, et al. A phase II trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large B-cell lymphoma. Blood. 2008;112(1):98–107.

320. Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015;14:207.
336. Tian Z, Zhao J, Tai YT, Amin SB, Hu Y, Berger AJ, Richardson P, Chau-D, Anderson KC. Investigational agent MLN9708/2238 targets tumor-suppressor miR336 in MM cells. Blood. 2012;120(19):3958–67.

337. Liu WCJ, Tamayo AT, Ruan C, Li L, Zhu S, Shen C, Young RH, Westin J, Davis RE, Hu S, Medeiros Li, Ford RJ, Pham LV. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget. 2017;9:346.

338. Chitta K, Paulus A, Akhtar S, Blake MK, Caulfield TR, Novak AJ, Ansell SM, Adami P, Laiawadi S, Sher T, et al. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenstrom macroglobulinemia tumour cells. Br J Haematol. 2015;169(3):377–90.

339. Hientz K, Mohra A, Bhakta-Guha D, Effert T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017;8(5):8921–61.

340. Luo Q, Pan W, Zhou S, Wang G, Yi H, Zhang L, Yan X, Yuan L, Liu Z, Wang J, et al. A novel BCL2 inhibitor APG-2575 exerts synthetic lethality with BTK or MDM2-p53 inhibitor in diffuse large B-cell lymphoma. Oncol Res. 2020;28(4):331–44.

341. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24(17):2899–908.

342. Ding Q, Zhang Z, Liu JJ, Ross TM, Jiang N, Zhang J, Ross TM, Chu XJ, Bartkovitz EM. XPO1-dependent nuclear export as a target for XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted with BTK or MDM2-p53 tumor cell death. EMBO Mol Med. 2021;13(2):852.

343. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24(17):2899–908.

344. Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, Chu XJ, Bartkovitz EM, Podlaski F, Janson C, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2021;54(14):5894–91.

345. Montesinos PBB, Catalani O, Esteve J, Gamel K, Konopleva M, Martellini G, Mommer A, Papayanond C, Park A, Recher C, Rodriguez-Vega R, Rolig C, Vey N, Wei AH, Yoon SS, Fenaux P. Discovery of T22-PE24-H6 to CXCR4(+) diffuse large B-cell lymphoma mouse models. Theranostics. 2020;10(3):741–53.

346. Alba-Castellon L, Alamo P, Unzueta U, Villaverde A, et al. Selective delivery of T22-PE24-H6 to CXCR4(+) diffuse large B-cell lymphoma cells leads to therapeutic index in a disseminated mouse model. Theranostics. 2020;10(12):5169–80.

347. Nakanaka Y, Yamamoto K, Morikawa Y, Oka T, Tsuchiya M, Nishimura H, et al. Selective delivery of T22-PE24-H6 to CXCR4(+) diffuse large B-cell lymphoma cells leads to therapeutic index in a disseminated mouse model. Theranostics. 2020;10(12):5169–80.

348. Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, et al. Venetoclax with dose-adjusted POACH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Lancet Haematol. 2021;8(11):e818–27.

349. Davies A, Cummin TE, Barrons S, Maishman T, Mamo C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, et al. Gene-expression profiling of tretinoin added to standard chemotherapy for diffuse large B-cell lymphoma (REMOCL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):649–62.

350. Oki Y, Kelly KR, Flinn I, Patel MR, Gharavi R, Ma A, Parker J, Hafeez A, Mucci R, Yones A. CDK inhibitor flavopiridol in DLBCL: a phase II trial. Haematologica. 2017;102(11):1923–30.

351. Ji J, Liu Z, Kuang P, Dong T, Chen X, Li J, Zhang C, Li J, Zhang L, Shen K, et al. A new conditioning regimen with cladribine, chlorambucil, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3.

352. Brum EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, Henry NL, Dillon H, Little RF, et al. SWOG 1918: A phase I/II randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in patients age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas—aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol. 2022;13(2):258–64.

353. Martin P, Bartlett NL, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Jones J, Drew J, Wu C, Mulvey E, et al. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood. 2022;139(8):1147–59.

354. Seymour K, Khan HY, Li Y, Chaker M, Muckli I, Aboukameel A, Ramchandren R, Houdé C, Sterbis G, Yang J, et al. Selinexor in combination with R-CHOP for frontline treatment of non-Hodgkin lymphoma: results of a phase I study. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(12):3307–16.

355. Schock LA, Asama A, Zahrakar M, Shanbhag S, Hurtt J, Sawyer K, Swinnen LJ, Wagner-Johnston N, Jones RJ, Ambinder RF, et al. Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients. Cancer Chemother Pharmacol. 2018;81(2):347–54.
371. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.

372. Dubois S, Mareschal S, Cornic M, Picquenot J-M, Bertrand P, Bohers E, Maingonnat C, Vailly P-J, Ruminy P, Alcantara M, et al. Targeted EZH2 inhibitors in diffuse large B-cell lymphoma (DLBCL): immunohistochemical and mutational profiles of patients may determine candidates for treatment. Blood. 2014;124(21):1656–1656.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.